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Abstract
Background: Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) are present in a subset of aquaporin-4
(AQP4)-IgG-negative patients with optic neuritis (ON) and/or myelitis. Little is known so far about brainstem
involvement in MOG-IgG-positive patients.
Objective: To investigate the frequency, clinical and paraclinical features, course, outcome, and prognostic
implications of brainstem involvement in MOG-IgG-positive ON and/or myelitis.
Methods: Retrospective case study.
Results: Among 50 patients with MOG-IgG-positive ON and/or myelitis, 15 (30 %) with a history of brainstem
encephalitis were identified. All were negative for AQP4-IgG. Symptoms included respiratory insufficiency, intractable
nausea and vomiting (INV), dysarthria, dysphagia, impaired cough reflex, oculomotor nerve palsy and diplopia, nystagmus,
internuclear ophthalmoplegia (INO), facial nerve paresis, trigeminal hypesthesia/dysesthesia, vertigo, hearing loss, balance
difficulties, and gait and limb ataxia; brainstem involvement was asymptomatic in three cases. Brainstem inflammation
was already present at or very shortly after disease onset in 7/15 (47 %) patients. 16/21 (76.2 %) brainstem attacks were
accompanied by acute myelitis and/or ON. Lesions were located in the pons (11/13), medulla oblongata (8/14),
mesencephalon (cerebral peduncles; 2/14), and cerebellar peduncles (5/14), were adjacent to the fourth ventricle in 2/12,
and periaqueductal in 1/12; some had concomitant diencephalic (2/13) or cerebellar lesions (1/14). MRI or laboratory signs
of blood-brain barrier damage were present in 5/12. Cerebrospinal fluid pleocytosis was found in 11/14 cases, with
neutrophils in 7/11 (3-34 % of all CSF white blood cells), and oligoclonal bands in 4/14. Attacks were preceded by acute
infection or vaccination in 5/15 (33.3 %). A history of teratoma was noted in one case. The disease followed a relapsing
course in 13/15 (87 %); the brainstem was involved more than once in 6. Immunosuppression was not always effective in
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preventing relapses. Interferon-beta was followed by new attacks in two patients. While one patient died from central
hypoventilation, partial or complete recovery was achieved in the remainder following treatment with high-dose
steroids and/or plasma exchange. Brainstem involvement was associated with a more aggressive general disease course
(higher relapse rate, more myelitis attacks, more frequently supratentorial brain lesions, worse EDSS at last follow-up).
Conclusions: Brainstem involvement is present in around one third of MOG-IgG-positive patients with ON and/or
myelitis. Clinical manifestations are diverse and may include symptoms typically seen in AQP4-IgG-positive neuromyelitis
optica, such as INV and respiratory insufficiency, or in multiple sclerosis, such as INO. As MOG-IgG-positive brainstem
encephalitis may take a serious or even fatal course, particular attention should be paid to signs or symptoms of
additional brainstem involvement in patients presenting with MOG-IgG-positive ON and/or myelitis.
Keywords: Myelin oligodendrocyte glycoprotein (MOG) antibodies, MOG-IgG, Neuromyelitis optica spectrum
disorders (NMOSD), Brainstem encephalitis, Rhombencephalitis, Optic neuritis, Myelitis, Longitudinally extensive
transverse myelitis (LETM), Cerebellitis, Ataxia, Respiratory insufficiency, Intractable nausea and vomiting, Facial nerve
palsy, Diplopia Internuclear ophthalmoplegia (INO), Hearing loss, Aquaporin-4 antibodies (AQP4-IgG, NMO-IgG)
Background
Over the past few years, a new diagnostic role has been
found for antibodies to myelin oligodendrocyte glycopro-
tein (MOG-IgG) in adults [1]. While MOG-IgG had ini-
tially been thought to play a role in classical multiple
sclerosis (MS), recent studies have demonstrated that
MOG-IgG are in fact a marker of autoimmune optic neur-
itis (ON) and (often longitudinally extensive) transverse
myelitis [1, 2]. Based on the fact that aquaporin-4 (AQP4)-
IgG is usually absent in MOG-IgG-positive patients [3–10],
that the histopathology of inflammatory CNS lesions
differs between MOG-IgG- and AQP4-IgG-positive patients
[11–13], and that MOG-IgG are pathogenic both in vitro
and in vivo [2, 14], MOG-IgG-related autoimmunity is now
considered by many a disease entity in its own right, distinct
both from classical MS and from AQP4-IgG-mediated neu-
romyelitis optica spectrum disorders (NMOSD) [15, 16].
While the association of MOG-IgG with ON and mye-
litis is now well established [2–4, 6, 17], less is known
about extra-opticospinal manifestations in MOG-IgG-
related autoimmunity. Here, we report the largest series
of Caucasian patients with MOG-IgG-positive brainstem
encephalitis so far. Brainstem involvement was severe in
some of the cases and was fatal in one patient. Clinical,
laboratory, and radiologic findings are reported in
addition to treatment outcomes.
This article is the third of a four-part series on the
clinical, laboratory, magnetic resonance imaging (MRI),
electrophysiological, and optical coherence tomography
features of patients with MOG-IgG-related CNS auto-
immunity [3, 17, 18].
Methods
All 15 patients were identified from a large European
cohort of almost exclusively Caucasian patients with
MOG-IgG-associated ON and/or myelitis (n = 50) from
12 European academic centers, eight of which are mem-
bers of the German Neuromyelitis optica study group
(NEMOS) [19–23]; this cohort is described in parts 1
and 2 of this series [3, 17]. MOG-IgG had been tested
for clinical purposes in all cases and was detected using
a live-cell-based assay (CBA) [2] and a commercial
fixed-cell CBA (Euroimmun, Luebeck, Germany), both
of which employ recombinant human full-length MOG
as antigenic substrate. AQP4-IgG was tested using a
commercial CBA (Euroimmun) employing recombinant
human full-length AQP4 [24–26] and was negative in all
cases [3]. The study was approved by the institutional
review boards of the participating centers. Patients gave
their informed consent for publication. The median
number of documented clinically apparent brainstem at-
tacks per patient was 1 (range 1-5); brainstem encephal-
itis was asymptomatic in three patients. In total, 27
brainstem events were analyzed, including 21 symptom-
atic brainstem attacks and 6 ON and/or myelitis attacks
that were associated with MRI evidence for concomitant
subclinical brainstem encephalitis. In 6 patients, the
brainstem was involved more than once. The patients’
median disease duration at last follow-up was 54 months
(range 10-507; over >24 months in 12/15 cases).
Case reports
As reliable tests for MOG-IgG have only recently be-
come available, comprehensive case series illustrating
the broad and heterogeneous spectrum of clinical mani-
festations, disease courses, and radiologic presentations
in MOG-IgG-positive patients are lacking so far. In par-
ticular, there are almost no detailed reports on patients
with brainstem encephalitis. To paint for the first time a
vivid ‘real-life’ picture of the disorder, which statistical
analyses alone cannot achieve, we decided to provide de-
tailed reports on all patients included in this study. Cases
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1, 2 and 3 are described below; reports on the remaining
12 cases are to be found in the Appendix. For a compre-
hensive summary of the patients’ clinical, radiological and
laboratory features see the Table 1. A selection of illustra-
tive MR images demonstrating brainstem damage in
MOG-IgG-positive patients is shown in Figs. 1 and 2.
Case 1 – Fatal rhombencephalitis in a patient with
recurrent ON and LETM
A previously healthy 44-year-old Caucasian woman first
developed right-sided ON in November 2003. Lumbar
puncture (LP) demonstrated a normal CSF white cell
count as well as normal CSF protein, glucose, and lactate
levels and negative oligoclonal bands (OCB). Brain MRI
revealed asymptomatic lesions in the right cerebellar
hemisphere and in the cerebral peduncle of the mid-
brain. Magnetic resonance imaging (MRI) of the spinal
cord was not performed. After treatment with intraven-
ous methylprednisolone (IVMP), vision returned to
normal. Extensive laboratory tests did not reveal any
infectious or rheumatologic cause of the patient’s
symptoms.
Up to 2010 ON attacks occurred once to twice
annually, but vision always returned to normal after
IVMP therapy. However, after another attack of ON in
August 2010, vision in the right eye dropped perman-
ently to 0.85 on the Snellen chart despite IVMP therapy.
In January 2011, the patient developed a first attack of
myelitis with accompanying brainstem encephalitis.
Symptoms included right hemiparesis, dysarthria, and
dysphagia. MRI showed no supratentorial brain lesions
but a T2 lesion in the medulla oblongata and a cervical
longitudinally extensive transverse myelitis (LETM)
lesion extending from C2 to C4 with gadolinium (Gd)
enhancement. LP again demonstrated a normal CSF
white cell count, normal CSF protein level, and negative
OCB. Treatment with IVMP was followed by complete
remission. In June 2011, after another attack of myelitis
with paraparesis, treatment of which with IVMP had
resulted in incomplete remission of the symptoms,
treatment with glatiramer acetate (GLAT) for suspected
MS was initiated.
After a relapse-free period of 1 year, two further
relapses (ON in May 2012 and myelitis with paraparesis
in July 2012) followed. While treatment with IVMP led
only to partial recovery, plasma exchange (PEX) treat-
ment (five exchanges) was followed by complete clinical
remission after both relapses. After the second relapse,
GLAT was stopped (July 2012) and natalizumab started.
However, treatment with natalizumab was discontinued
after two infusions due to recurrent headaches.
In September, October, and December 2012 three further
relapses of myelitis with paraparesis occurred. PEX (five ex-
changes; no IVMP) resulted in partial recovery in all cases.
In January 2013, the patient received a first infusion of
mitoxantrone (12 mg/m2, nadir 3000/μl), and after a further
myelitis relapse with paraparesis in February 2013, a second
mitoxantrone infusion was given (8 mg/m2, nadir 2800/μl).
Complete recovery was achieved following PEX (five ex-
changes; no IVMP). After a further flare-up of myelitis later
the same month with paraparesis and Gd enhancement at
levels T2, T3, T5, and T9, treated with a cycle of five plas-
maphereses with incomplete remission in February 2013, a
third infusion of mitoxantrone with 8 mg/m2 was given. A
serum sample taken at that time later tested positive for
MOG-IgG in a live-cell CBA [2] (1:1280). Early in 2013,
two new ON relapses occurred and were treated with a
cycle of PEX (five exchanges), again with incomplete remis-
sion. MRI now showed Gd enhancement in large parts of
the thoracic spinal cord. An expanded disability status scale
(EDSS) score of 6 was documented at that time. MOG-IgG
were retrospectively positive at a titer of 1:640.
Rituximab (500 mg) was infused for the first time in
May 2013, followed 2 weeks later by a second infusion
of 500 mg rituximab. Fifteen days after the second infu-
sion the patient’s paraparesis worsened (EDSS 8) and
dysarthria re-occurred. Cerebral and spinal MRI showed
active lesions with Gd enhancement at the C4/C5 level,
in the pons, and in the medulla oblongata. After PEX
(five exchanges; no IVMP), the patient was able to walk
again and her dysarthria completely remitted. Two new
myelitis relapses in July and August 2013 with parapar-
esis (EDSS 7.5) and dysarthria were again treated with
PEX (five exchanges; no IVMP), which was followed by
partial recovery. MRI showed a new inactive lesion in
the pons in July 2013 and in August 2013 Gd enhance-
ment extended from C2 to C5. After a second PEX
cycle, urosepsis occurred and was treated successfully
with antibiotics. The next relapse occurred in November
2013 with a left ON (visual acuity of 0.05), which remit-
ted incompletely after one cycle of PEX (five exchanges)
(EDSS 7.5).
In January 2014, massive deterioration of the brainstem
symptoms occurred, with dysarthria, dysphagia, left oculo-
motor and facial nerve palsy, and new T2-hyperintense le-
sions in the pons, pedunculus cerebellaris, cerebral crus,
and medulla oblongata. No supratentorial lesions were seen
on brain MRI. Spinal MRI demonstrated a diffuse, asymp-
tomatic T2-hyperintense lesion from C2 to C4 as well as
patchy Gd enhancement in the pons, medulla oblongata,
and the entire cervical spinal cord. The patient was treated
with two courses of five PEX each (no IVMP) and initially
improved. In the following month, however, clinical symp-
toms deteriorated again and the patient developed bilateral
blindness and central hypoventilation. She was transferred
to palliative care and died in May 2014.
The total number of attacks in this patient was 25, 15
of which occurred under various immunomodulatory
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Table 1 Clinical, radiological and laboratory findings in 15 MOG-IgG-positive patients with a history of brainstem involvement
#1 #2 #3 #4 #5 #6 #7 #8
Sex Ff f f f f f m m
Ethnicity Cauc Cauc Cauc Cauc Cauc Cauc Cauc Cauc
BSTI at onset y y n n n n n n
Age at first
evidence for BSTI
(years)
53 18 45 35 31 53 19 19
Time to first
evidence for BSTI
(years)
0 0 18 0.75 0.25 41 0.3 0.17
No of clinical BST
attacks
5 1 2 3 1 0 1 1
No of attacks with
subclinical BSTI
2 0 0 0 0 1 0 1
Clinical BST
findings
Central hypoventilation,
dysphagia, dysarthria, CN III and VII
paresis
Respiratory
impairment,
difficulties
coughing,
dysphagia,
dysarthria,
diplopia
Cerebellar gait and upper
limb ataxia
Impaired
balance,
vertigo
Intractable nausea
and vomiting
None,
subclinical BST
involvement
Double vision and
gait ataxia
Hearing loss
Infratentorial MRI
findings
MRI1: Cerebral peduncle of the
midbrain, MO, pons, MRI2: MO,
new T2 lesions, Gd+, MRI3:
pedunculus cerebellaris, crus
cerebri, patchy Gd + pons, MO
Pontine
tegmentum and
cerebellar
peduncles
Crus cerebri and entire pons,
around the 4th ventricle,
extending into the left
cerebellar hemisphere
Pons and
medulla
oblongata
Right and left
dorsal MO, ad-
jacent to the 4th
ventricle, incl. the
area postrema
MO with
patchy Gd
enhancement
Lesions in the
peri-aqueductal
gray, ventral pons
T2 lesion in the pons
Cerebral
peduncles
y n y n n n n n
Pons y y y y n.d. n y y
Cerebellar
peduncles
y y n n n n n n
Cerebellum n n y n n n n n
Medulla oblongata
y n y y y y n n
Bulbo-spinal
lesion, ever
y n n y y y n n
Gd+, ever y n y y y y y y
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Table 1 Clinical, radiological and laboratory findings in 15 MOG-IgG-positive patients with a history of brainstem involvement (Continued)
Supratentorial MRI
findings
Normal T2-hyperintense
lesions in the
frontal and
parietal
subcortical white
matter
Crus cerebri, left subcort.
white matter (adjacent to
the temporal horn), corpus
callosum, juxtacortical
regions of parietal lobes
Lateral
ventricular
lesions
Normal Normal Confluent T2
hyperintense
lesions in the
right temporal
lobe, pulvinar
bilaterally
T2 lesions in basal ganglia,
corpus callosum, periventr.,
pulvinar thalami, rostral
putamen; leptomeningeal
contrast enhancement
Postinfectious/
postvaccinal
n y n n n y n y
Simultaneous ON
and BSTI
y n n n n n n y
Simultaneous MY
and BSTI
y y n y y y y y
History of both
ON and MY
y n n y y y y y
Recurrent disease y n y y y y y y
NMOSD 2015 n n y y y n y y
CSF-restr. OCB n n n y n.d. n y y
CSF WCC normal 360 50 normal 122 30 22 60
CSF neutrohils n.a. 7 % 6 % n.a. 3 % n.d. 6 % 26 %
QAlb elevated n.d. y n.d. n n y n y
Last EDSS 10 1 7.5 3 3 4.5 1 0
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Table 1 Clinical, radiological and laboratory findings in 15 MOG-IgG-positive patients with a history of brainstem involvement (Continued)
#9 #10 #11 #12 #13 #14 #15
Sex m m f f f f f
Ethnicity Cauc Cauc Cauc Cauc Cauc Cauc Cauc
BSTI at onset y y y y n y n
Age at first
evidence for BSTI
(years)
50 37 44 27 26 25 22
Time to first
evidence for BSTI
(years)
0 0 0 0 1.7 0 0
No of clinical BST
attacks
0 1 1 1 1 2 1
No of attacks with
subclinical BSTI
1 0 0 0 1 0 0
Clinical BST
findings
None,
subclinical
BST
involvement
Trigeminal
hypesthesia
None,
subclinical
BST
involvement
Trigeminal hyp- and paresthesia, diplopia,
nystagmus, unsteady gait
Hypesthesia tongue and face,
impaired smooth pursuit
Hemihypesthesia
including the face
INO
Infratentorial MRI
findings
Median
pontine
lesion
N.d. Cerebellar
peduncle,
single lesion
T2 lesions extending from the ponto-med.
junction, throughout the MO to C5, incl.
around the 4th ventricle
T2 lesions in the MO and
pons, detectable over a period
of at least 12 months
Bilateral pontine lesions
and bilateral cerebellar
peduncle lesions
Large, Gd + lesion: pons bilat., both
pedunculi cerebelli, paramedian
ponto-medullary junction
Cerebral
peduncles
n n.d. n n n n n
Pons y n.d. n y y y y
Cerebellar
peduncles
n n.d. y n n y y
Cerebellum n n.d. n n n n n
Medulla oblongata
n n.d. n y y n y
Bulbo-spinal
lesion, ever
n n.d. n y n n n
Gd+, ever y n.d. n.d. n n n.d. y
Supratentorial MRI
findings
Normal Normal Single frontal
lobe lesion
Juxta-cortical T2 lesion, insular region Callosal, periventr.,
juxtacortical, deep white
matter
Single small lesion
directly adjacent to the
left lateral ventricle
Peritrigonally and corona radiate, Gd
+
Postinfectious/
postvaccinal
y n n.d. n n y n
Simultaneous ON
and BSTI
y y n y n n n
Simultaneous MY
and BSTI
y y y y y n y
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Table 1 Clinical, radiological and laboratory findings in 15 MOG-IgG-positive patients with a history of brainstem involvement (Continued)
History of both
ON and MY
y y y y y n y
Recurrent disease y n y y y y y
NMOSD 2015 n n y y y n y
CSF-restr. OCB n n n n y n n
CSF WCC normal 8 n.d. 59 33 150 8
CSF neutrohils n.a. 34 % n.d. n.a. n.d. 26 % n.d.
QAlb elevated n n n.d. n n y y
Last EDSS 1 0 2.5 0 3.5 3 0.5
Abbreviations: BSTI brainstem involvement, y yes, n no, n.a. not applicable, n.d. no data, f female, m male, Cauc Caucasian, MO medulla oblongata, Gd + gadolinum enhancing, CN cranial nerve, MRI magnetic resonance
imaging, MY myelitis, ON optic neuritis, NMOSD 2015 neuromyelitis optica spectrum disorder according to Wingerchuk et al. (2015), CSF cerebrospinal fluid, OCB oligoclonal bands, QAlb albumin CSF/serum ratio, EDSS
extended disability status scale, INO internuclear ophthalmoplegia
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and immunosuppressive therapies. These included
around 13 relapses of ON and 12 of myelitis; the
brainstem was clinically affected during 5 attacks. This
corresponds to an annualized relapse rate of 2.38,
though 15/25 relapses occurred during the last
24 months before the patient’s death.
Case 2 – Single episode of post-infectious whole-spine
myelitis with severe brainstem and brain involvement yet
complete recovery
An 18-year-old Caucasian woman had purulent tonsillitis
in June 2010 and was treated with amoxicillin for 5 days.
About 1 week later she developed intermittent fever (up to
39 °C), general malaise, headaches, meningism, fluctuating
diplopia on right gaze, and subtle psychomotor slowing, for
which she was admitted to the Department of Neurology,
Charité – University Medicine Berlin. The day after admis-
sion, her condition deteriorated and she additionally noted
weakness of her legs, urinary incontinence, respiratory im-
pairment with difficulty in coughing, and mild dysphagia.
On neurologic examination the patient was awake and
oriented. Cranial nerve examination showed no abnormal-
ities, but she had marked dysarthria and reported fluctuat-
ing horizontal diplopia. Her legs were plegic and she had
reduced pain and touch sensation below T10. There was
also British Medical Research Council (BMRC) grade 4
distal weakness in both arms. Deep tendon reflexes were
preserved throughout. Except for a mature cystic ovarian
teratoma without signs of malignancy, which had been
removed 2 months before, her past medical history was
unremarkable. N-Methyl-D-aspartate receptor (NMDAR)
antibodies were negative. Spinal MRI demonstrated a
prominent, longitudinally extensive, T2-hyperintense and
centrally located lesion without contrast enhancement
extending over almost the entire spinal cord, as well as
swelling of the cord (Fig. 2). Cranial MRI showed T2-
hyperintense lesions in the frontal and parietal subcortical
white matter, the pontine tegmentum, and the cerebellar
peduncles without contrast enhancement (Fig. 1). Thor-
acic and abdominal MRI revealed a right retroperitoneal
mass with a diameter of 5.6 cm, which was resected
5 months later and found to be a ganglioneuroma. CSF
analysis on the day of admission demonstrated an elevated
total cell count with 306 white blood cells/μl (reference
range <5/μl) with 80.2 % lymphocytes, 8.2 % monocytes,
7 % neutrophils, 2.4 % eosinophils, and 2.2 % activated
lymphocytes, but no plasma cells or tumor cells. CSF
lactate was elevated at 28.4 mg/dl (reference range
<20 mg/dl). There was moderate blood–CSF barrier
(BCSFB) dysfunction with an albumin CSF/serum ratio
(QAlb) of 30.6 × 10-3 (age-adjusted upper limit of normal
5.2 × 10-3). Accordingly, total CSF protein was elevated
(213 mg/dl; reference range <45 mg/dl). She had no local
IgG synthesis and no CSF-specific OCB.
Routine serum chemistry including C-reactive protein
(CRP) showed normal results. A complete blood count
revealed mild leukocytosis (12.44/nl; reference range
<11/nl). Extensive microbiological (herpes simplex virus
type 1 and 2, varicella zoster virus, Epstein–Barr virus,
cytomegalovirus, human herpes virus 6, enteroviruses,
influenza A virus, adenovirus, tick-borne encephalitis
virus, human immunodeficiency virus, human T-cell
leukemia virus type 1, Borrelia, Treponema pallidum,
Brucella, Bartonella, Mycoplasma, Chlamydia, Mycobac-
terium tuberculosis, Aspergillus) work-up detected no
signs of acute CNS infection.
Antinuclear antibodies were detectable at a titer of
1:1280, but antibodies to double-stranded DNA,
extractable nuclear antigens, onconeuronal antigens
(Hu, Yo, Ri, CV2/CRMP5, Ma2/Ta, amphiphysin), cardi-
olipin, β2-glycoprotein, phosphatidyl serine, gangliosides
(GD1a, GD1b GM1, GM2, GM3, GQ1b, GT1b [IgG and
IgM in each case]), and aquaporin-4 were negative, as
were anti-neutrophil cytoplasmic antibodies. Screening
of serum and CSF for antibodies against NMDA recep-
tors (IgG, IgA, IgM), alpha-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) receptors, glycine
receptor, myelin-associated antigen, and glutamic acid
decarboxylase was likewise negative.
However, testing of a serum sample obtained on the
day of admission in a live-cell CBA demonstrated high-
titer serum IgG antibodies against MOG (1:10240).
Anti-MOG antibodies were also detectable in the CSF
(1:64), but there was no evidence of intrathecal produc-
tion of anti-MOG antibodies, with an anti-MOG anti-
body index (AI) of 0.3 (reference range <4) [3].
The patient was initially treated with ceftriaxone and
ampicillin, which was discontinued after a bacterial in-
fection was ruled out, as well as with IVMP (1 g/day for
6 days). Corticosteroids were thereafter administered or-
ally (prednisolone 100 mg/d), slowly tapered, and even-
tually stopped in October 2010. Starting on the day after
admission, she was additionally treated with a total of 10
PEX. MOG-IgG was retrospectively detectable also in
PEX plasma (titer 1:320 after three exchanges). There-
after, therapy with intravenous immunoglobulins (IVIG,
2 g/kg body weight) was initiated in July 2010. IVIG
therapy was continued at 5-week intervals until June
2011, with dose reduction to 1 g/kg body weight from
January 2011 onwards. The patient gradually recovered
and was able to walk with a walking frame by
August 2010. Follow-up spinal MRI in August 2010
demonstrated resolution of the longitudinal extensive
lesion, but there were several residual patchy hyper-
intense lesions within the spinal cord. In a serum sample
obtained at the same time, the anti-MOG antibody
titer was clearly lower (1:640) than the initial titer, and
anti-MOG antibodies were no longer detectable in CSF.
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The patient did not receive any further immunomodu-
latory or immunosuppressive therapy. At the last follow-
up examination, 28 months after disease onset and
16 months after discontinuation of IVIG, she reported
no further relapses and had no impairments in activities
of daily living except for residual unsteadiness when
walking for a longer time, difficulties on running for
more than 5 min, and slightly increased urinary fre-
quency (EDSS 1). Neurologic examination showed a very
mild residual right-sided pyramidal syndrome with brisk
tendon reflexes, but was otherwise unremarkable.
Case 3 – Recurrent ON with rhombencephalitis and
extensive brain involvement with poor outcome
A Caucasian woman experienced a first episode of
bilateral ON in 1985 at age 28 and had three further
attacks of bilateral and two of unilateral ON up to 1999,
leaving her with residual visual acuity of <0.2 in both
eyes. CSF and brain MRI was normal. In October 2003,
the patient presented with intractable headaches lasting
for several days, followed by mild impairment of
consciousness. Cerebral computed tomography showed
no abnormalities, while CSF analysis disclosed mixed
lymphocytic and neutrophilic pleocytosis (1024 cells/μl)
along with increased total protein (1350 mg/l) and
mildly elevated lactate (3.6 mmol/l). CRP and leukocytes
were elevated at 18 mg/l and 20.9 Gpt/l, respectively.
There was no evidence of an infectious etiology, and
symptoms resolved after combined treatment with
dexamethasone 10 mg 4× per day for 4 days and ceftri-
axone 4 g daily for 10 days. However, within 2 weeks the
patient developed bilateral intention tremor of the upper
extremities, marked gait ataxia, and right-sided visual
worsening. Cranial MRI revealed extensive T2 hyperin-
tense lesions in the brainstem, including around the
fourth ventricle and in the supratentorial white matter,
the corpus callosum, and, to some extent, the cerebral
cortex. None of these abnormalities showed Gd en-
hancement. The CSF had 50 white cells/μl, mostly
lymphocytes with some neutrophils (6 %) and occasional
eosinophils (2 %). Treatment with IVMP (1 g/d for
5 days) followed by oral tapering of steroids for 6 weeks
resulted in marked improvement of symptoms.
Six months later, the patient noted visual worsening in
the left eye and recurrence of gait ataxia. Repeat cranial
MRI depicted progressive T2-hyperintense lesions in the
entire pons, especially around the fourth ventricle and
the foramina of Luschka, extending bilaterally into the
white matter of the left cerebellar hemisphere and into
the crus cerebri with Gd enhancement. There was also
involvement of the left subcortical white matter
(adjacent to the temporal horn), the corpus callosum,
and the juxtacortical regions of both parietal lobes, along
with contrast enhancement in some of these lesions.
Cerebral angiography showed no abnormalities. CSF
analysis showed 5 cells/μl with a predominance of
lymphocytes and some neutrophils and eosinophils.
There was no evidence of intrathecal immunoglobulin
synthesis. Anti-Hu and anti-Yo antibodies were negative.
The patient received 1000 mg methylprednisolone i.v.
daily for 5 days and subsequently long-term oral ste-
roids, and this coincided with partial amelioration of
both clinical symptoms and radiologic findings. Night-
mares and visual hallucinations resolved along with
rapid tapering of steroid doses. For long-term immuno-
suppression, overlapping treatment with azathioprine
(AZA) (150 mg/day) was initiated in August 2004. How-
ever, five more relapses occurred over the following
101 months despite AZA treatment. At last follow-up,
the EDSS of 7.5 and bilateral optic nerve atrophy (in-
volving the chiasm) was documented. Retrospective test-
ing of a serum sample taken in 2010 revealed high-titer
MOG-IgG (1:20,480). MOG-IgG seropositivity was
confirmed in a second sample obtained 22 months later.
Discussion
We describe the largest series to date of MOG-IgG-positive
patients with brainstem involvement, thereby expanding
the clinical spectrum of MOG-IgG autoimmunity. The 15
cases presented here were identified as part of a large
European cohort (n = 50) of MOG-IgG-positive patients
reported in part 1 [3] and part 2 [17] of this series, suggest-
ing a relatively high frequency (30 %) of brainstem involve-
ment among patients with MOG-IgG-associated myelitis
and/or ON. Similarly, AQP4-IgG-positive NMO, also
initially thought to affect mainly the optic nerves and spinal
cord, was later reported to involve the brainstem in up to
one third of all cases [16, 20, 27, 28]. We detected MOG-
IgG by means of new-generation cell-based assays (CBA)
employing recombinant full-length human MOG instead of
enzyme-linked immunoassays, which are prone to both
false-negative and false-positive results and which are no
longer recommended for routine clinical diagnosis of MOG
antibodies [2]; CBAs were also used for detecting AQP4-
IgG [24, 25]. It is a further potential strength of this study
that all patients analyzed were of Caucasian descent. This
may be important since genetic factors are thought to play
a role in NMO and related disorders [29].
The cases described here underline our finding from
part 2 [17] that MOG-IgG-related CNS autoimmunity is
not mostly a mild and monophasic disease, as suggested
by some earlier studies with smaller sample sizes and
shorter observation periods [4, 6], but can in fact take a
relapsing and severe disease course with potentially
life-threatening complications: brainstem involvement
caused respiratory impairment in two patients in our
series and was fatal in one of them. Respiratory insuffi-
ciency due to brainstem inflammation has previously
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Fig. 1 Examples of the magnetic resonance imaging (MRI) findings in patients with MOG-IgG-positive brainstem encephalitis. a-c Patient
12: T2-hyperintense lesions extending from the pontomedullary junction throughout the cervical cord as far as C5; lesions included the
dorsal medulla oblongata (B, arrow). d-h Patient 8: T2-hyperintense lesions in the pons, midbrain, thalamus, and basal ganglia; lesions
involved the periependymal surfaces of the third ventricle. j-k Patient 4: T2-hyperintense lesions in the right (j) and left (k) half of the
dorsal medulla oblongata including the area postrema (j). l-n Patient 2: T2-hyperintense lesions in the frontal and parietal subcortical
white matter, the pontine tegmentum, and the cerebellar peduncles (arrows)
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been identified as the main cause of death in AQP4-
IgG-positive NMO [30].
Besides central hypoventilation, the patients’ symptoms
included dysarthria, dysphagia, impaired cough reflex,
sensory impairment due to trigeminal nerve damage, facial
nerve palsy, trigeminal hypesthesia, oculomotor nerve palsy
and diplopia, nystagmus, internuclear ophthalmoplegia
(INO), vertigo, hearing loss, balance difficulties, gait and
limb ataxia, and, of particular note, intractable nausea and
vomiting (INV).
Brainstem symptoms included intractable nausea and
vomiting
INV in patients with brainstem encephalitis is caused by
lesions in the dorsal medulla oblongata (area postrema).
While presence of an area postrema syndrome (APS) has
hitherto been considered to have high predictive value for
a diagnosis of AQP4-IgG-positive NMO [15, 31–35], our
study demonstrates that area postrema lesions and INV
also occur in MOG-IgG-positive patients. However, this is
not totally unexpected. First, MOG is expressed through-
out the entire CNS and, accordingly, inflammatory lesions
were found in almost all areas of the CNS in our cohort
[17]; there is a priori no reason why the area postrema in
particular should be spared. Second, it has been spec-
ulated that the circumventricular organs, including
the area postrema, which lack a proper blood-brain
barrier (BBB), may be sites prone to entry of AQP4-
IgG into the CNS; assuming MOG-IgG are pathogenic
(as suggested by recent studies [2, 14]), this would also
be relevant for MOG-IgG.
Inflammation occurred in all areas of the brainstem
Apart from the pons, which was affected in 11/13 (84.6 %)
patients, MRI brainstem lesions were most commonly
located in the medulla oblongata (8/14 or 57.1 %), in the
mesencephalon (lesions in the cerebral peduncles in 2/14
or 14.3 %), and in the cerebellar peduncles (5/14 or 35.7 %).
Additional involvement of the diencephalon and the
cerebellum
In several cases brain involvement on MRI was not
restricted to the brainstem. Concomitant diencephalic
(pulvinar) and cerebellar lesions – and thus rhombencepha-
litis – were present in 2/13 (15.4 %) and 1/14 (7.1 %),
respectively. In case 3, an additional lesion was present in
the cerebellum which was accompanied by limb ataxia and
marked gait ataxia. Cerebellar gait and stance ataxia was
Fig. 2 Serial MRI examination of patient 1. a Sagittal T2 weighted baseline MRI showing no involvement of the brainstem or of the spinal cord.
b-e Follow-up MRI 5 month later revealed a new spinal cord lesion extending over 4 vertebral segments with cord swelling on T2-weighted
imaging as well as new lesion formation in the pons and medulla oblongata with gadolinium enhancement on T1-weighted imaging. Within the
following 5 months clinical symptoms deteriorated further with infratentorial T2 lesion enlargement and new lesion formation in the pons, e.g.
adjacent to the middle cerebellar peduncle, accompanied by gadolinium enhancement (f)
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also noted in case 2 as well as cerebellar dysarthria.
Similarly, patient 9 in part 2 [17] presented with a (clinically
silent) lesion in the cerebellar white matter; however, that
patient had no lesions in the brainstem. Cerebellar symp-
toms have very rarely been described in AQP4-IgG-positive
patients, too [20]. However, not all patients with ataxia had
cerebellar lesions; some patients in this and in the total
cohort [17] presented with sensory ataxia and/or unsteady
gait due to paresis caused by acute myelitis.
Supratentorial brain lesions were present in 10/15
(66.7 %) patients. Lesions were found in the deep (including
the periventricular) white matter (including in the corona
radiata), the sub-/juxtacortical white matter (including in
the insula), and, in a single patient, to some extent the cere-
bral cortex; furthermore, in the corpus callosum and, in one
case, the basal ganglia and thalami (see part 2 of this series
for exemplary MRI images [17]). In patient 3, brain and
brainstem lesions were extensive and even resulted in im-
paired consciousness. Similarly, extensive confluent supra-
tentorial lesions were seen in patient 7. Barkhof ’s MRI
criteria for MS were met in 4/15 (26.7 %) patients.
Acute brainstem involvement was associated with ON
and/or myelitis in most cases
Isolated attacks of brainstem encephalitis, i.e., attacks that
were not accompanied by clinical symptoms of ON or
myelitis, were very rare in the total cohort of 50 MOG-
IgG-positive patients [17], accounting for only 5/276
(1.8 %) documented attacks. However, they were relatively
common if only patients with a history of at least one
brainstem attack are taken into account (5/21 [23.8 %]
attacks, 4/15 [26.7 %] patients).
In most patients, however, brainstem attacks were
at least once associated with clinical myelitis (13/15
[86.7 %] patients), ON (6/15 [40 %]) and/or supraten-
torial encephalitis. In 5 out of 14 patients (36 %) with
a history of simultaneous brainstem encephalitis and
myelitis and available MRI data, lesions contiguously
stretched from the medulla oblongata into the cer-
vical cord at least once, similar to what can be seen
in AQP4-IgG-positive patients. In case 2, inflamma-
tion affected almost the entire neuraxis, including the
lumbar, thoracic, and cervical spinal cord as well as
areas in the brainstem and in the supraventricular
white matter. This was associated with exceptionally
high MOG-IgG serum titers (1:10,240) and presence
of detectable MOG-IgG levels also in the CSF.
Some patients met Wingerchuk’s criteria for NMO(SD)
At last follow-up, 12/15 (80 %) patients with brainstem
encephalitis had a history of both ON and myelitis. Two
patients had a history of myelitis but not of ON, and
one had a history of recurrent ON (rON) but not of
myelitis. All but 2 (86.7 %) had a relapsing disease
course at last follow-up. Of those 12 patients, 8 (66.7 %)
met the 2006 Wingerchuk criteria for NMO [36]; in the
remaining 4 patients, the criteria were not fulfilled due
to the presence of brain MRI lesions at onset meeting
Paty’s criteria and/or because criteria for LETM were
not met. On the understanding that MOG-IgG-positive
ON and/or myelitis are not considered “alternative
diagnoses”, i.e., based solely on clinicoradiologic find-
ings, 9/15 (60 %) met the revised 2015 consensus criteria
for NMOSD.
Brainstem involvement may be asymptomatic
While overall there was a high degree of agreement
between MRI findings and clinical presentation, in 5/15
(33.3 %) patients asymptomatic brainstem lesions were
detected by MRI at least once, suggesting that subclin-
ical brainstem encephalitis is not uncommon in MOG-
IgG-related CNS autoimmunity. The true prevalence of
brainstem involvement in MOG-IgG-positive patients
may thus be higher than expected based solely on
clinical presentation. Similarly, evidence for subclinical
involvement of the brain, the spinal cord, or the optic
nerves, as detected by MRI or electrophysiology, has
been found in some of our MOG-IgG-positive patients
(see part 2 of this series for details [17]).
CSF and MRI findings may mimic infectious CNS disease
In one case, leptomeningeal contrast enhancement was
noted at the time of disease onset. This is of particular
interest in the light of recent studies indicating the
existence of a lymphatic system of the CNS within the
meninges [37]. Meningeal involvement has been re-
ported in neuromyelitis optica [38–43], MS, and other
disorders of putative autoimmune etiology and may
indicate a new path for immune cell entry into the CNS.
Moreover, this finding is of potential differential diag-
nostic relevance, since it may wrongly suggest acute
infectious meningitis, all the more as CSF findings com-
patible with an infectious etiology were found in some
patients: CSF pleocytosis was present in 11/14 (78.6 %)
patients (50/μl, range 8-360) with available data and
comprised neutrophil granulocytes in 7/11 (63.6 %) (ac-
counting for 3-34 % of all white CSF cells) or eosinophil
granulocytes in 2/6 (33.3 %), increased lactate levels in 2/3
(66.7 %) patients, BCSFB dysfunction in 5/12 [41.7 %],
and CSF-restricted OCB, a mainstay of classical MS, were
absent in 10/14 (71.4 %). Together with fever and other
signs of systemic infection – disease onset was preceded
by acute infections in at least three patients (purulent
tonsillitis, ENT infection, and bronchopulmonary infec-
tion, respectively) – these CSF findings are compatible
with early bacterial or viral meningoencephalitis and thus
bear the risk of delayed diagnosis of autoimmune
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encephalitis, as was the case in one of the patients
reported here. Neutrophilic and eosinophilic pleocytosis
[20, 44, 45], elevated lactate levels [45, 46], and missing
OCB [45, 47] are also features of AQP4-IgG-positive
NMO. Elevated neutrophil counts have been previously
reported also in MOG-IgG-positive pediatric patients [48].
Moreover, attacks are preceded by acute infection in
20-30 % of cases of AQP4-IgG-positive NMO [20, 49, 50],
suggesting that infection-related immunologic changes
or infection-related BBB disruption [45, 47] may trig-
ger disease activity.
Post-infectious onset and the role of BBB damage
In one of the three patients with post-infectious onset
(case 6), interruption of long-term MTX treatment for RA
due to infection was followed by the first attack a few
weeks later, leaving the possibility that MOG-IgG were
already present before clinical onset but were able to enter
the CNS to a pathologically relevant degree only after
infection-related BBB breakdown. In fact, a markedly
elevated QAlb as well as Gd entry into the lesion was
noted during acute brainstem encephalitis in that case. In
AQP4-IgG-positive NMO, the autoantibody has indeed
been retrospectively demonstrated in samples obtained
months or years before disease onset [51–53]. Overall, 8/9
patients showed Gd enhancement during disease activity,
and 3/7, including the single patient without Gd en-
hancement, had an increased QAlb, indicating possible
BBB disruption. Primary or secondary impairment of
the BBB function may be an important step in the
pathogenesis of MOG-IgG-positive brainstem encephalitis,
since it may allow MOG-IgG to enter the CNS.
In one patient, the first symptoms developed within
2 weeks after vaccination for diphtheria, tetanus, pertussis,
polio, and influenza, and thus within a time window consid-
ered to be compatible with a post-vaccination reaction. Of
note, we describe a second adult patient with disease onset
shortly after vaccination against diphtheria, tetanus and
pertussis in part 2 of this series [17]. The association of
MOG-IgG seropositivity with infection and vaccination
deserves to be investigated in more detail. MOG-IgG have
also been reported in children with acute disseminated
encephalomyelitis [1], a condition with suspected post-
infectious or post-vaccinal etiology [54, 55]. Postvaccinal
onset of NMO has been described also in a few AQP4-IgG-
positive patients, although a causal link has not yet been
proven [56, 57].
MOG-IgG positivity associated with a mature teratoma
Both MOG-IgG-positive encephalomyelitis and AQP4-IgG-
positive NMOSD are not usually found in a paraneoplastic
context. It is therefore of potential interest that one of the
patients described above had a history of mature teratoma
that was removed just 2 months before onset of her CNS
disorder. In addition, a ganglioneuroma was detected after
disease onset in the same patient. It remains unknown
whether this patient’s tumors and MOG-IgG seropositivity
were related. Teratomas have been shown to play a
role in the pathogenesis of NMDAR encephalitis, another
autoantibody-related disorder of the CNS [58]. However,
NMDAR antibodies were negative in our patient. While,
to the best of our knowledge, the presence of MOG
in teratomas has not been investigated so far, expres-
sion of CNPase, an oligodendrocyte marker, has been
described in mature teratomas [59], and several
reports on oligodendrogliomas arising in mature tera-
tomas exist [60–63]. Ectopic expression of MOG by
the patient’s tumor therefore cannot be completely
ruled out.
Influence of age and sex
The median age at first clinical brainstem attack was
31 years (range 18-53 years) in the present, adult cohort.
This did not differ from the age of disease onset in the
total MOG cohort (see part 2 [17]) (31 years, range
6-70; N = 50). Remarkably, in 7/15 (46.7 %) cases brain-
stem inflammation (as evidenced clinically or by MRI)
was already present at or very shortly after disease onset.
In the remainder, the median time between disease onset
and first clinically apparent brainstem encephalitis was
just 0.8 years. However, this interval varied widely, with
brainstem lesions occurring for the first time only 7, 17,
and 41 years, respectively, after the first attack in three
patients. Together, these findings suggest that the
presence or absence of brainstem involvement is not an
effect of age or disease duration.
The sex ratio in our cohort (1:2.8) did neither differ
from that previously reported in AQP4-IgG-negative
NMO patients with and without brainstem lesions (1:2;
n = 27) [20] nor from that in the total MOG cohort
(1:2.8; n = 50) [17] (but is in stark contrast to the sex
ratio of ~1:9 reported in AQP4-IgG-positive patients
[20]), indicating that female gender is probably not a risk
factor for the development of brainstem involvement in
patients with MOG-IgG-positive ON and/or myelitis.
Good recovery from acute brainstem attacks after IVMP
and/or PEX
While many patients seemed to benefit from immuno-
therapy, treatment responses and long-term outcomes
differed markedly. Treatments applied during acute
brainstem attacks (with and without concomitant ON
and/or myelitis) included IVMP, oral steroids, and PEX.
Overall, treatment outcome was available for 18 attacks
with clinical brainstem involvement. Treatment with
IVMP (with and without oral tapering) or with PEX
(with or without additional IVMP) were followed by
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good partial recovery after 6 and 3 brainstem attacks,
respectively, and by full recovery after 3 and 3 brainstem
attacks, respectively. No treatment was given for the last
(and subsequently fatal) attack in patient 1, which oc-
curred during palliative care, for two brainstem attacks
in case 5, which remitted spontaneously, and for the
only attack in case 5 (initially considered to be of
infectious origin due to granulocytic pleocytosis), which
partially remitted.
PEX treatment was beneficial in patient 1 during most
attacks, including three brainstem attacks and one attack in
which IVMP had led only to partial recovery. Similarly,
PEX also resulted in full or almost full remission when used
to treat attacks with brainstem involvement in patients 6
and 8 (used in combination with IVMP), as well as in
patient 9 after failure of high-dose IVMP therapy.
Importantly, however, PEX treatment could not
prevent relapses 1-3 months later in case 1, including
the fatal brainstem attack in that patient, as well as a
relapse of ON within 2 months in patient 9. Prelimin-
ary findings from our laboratory (S.J., unpublished data)
show that anti-neural autoantibodies may remain detect-
able or reappear soon after five to seven plasma ex-
changes, raising the question of whether PEX treatment
may be discontinued too early in some cases. Alterna-
tively, T cell-mediated mechanisms may play a more
important role in patients who do not sufficiently respond
to PEX.
Both IVMP and PEX were also not always effective
when used to treat attacks other than brainstem enceph-
alitis in this cohort and in the total cohort (see part 2 for
detailed analysis [17]).
Long-term immunotherapy did not prevent brainstem
attacks in some patients
Immunosuppressive or immunomodulatory (IS/IM)
drugs used in our patients included mitoxantrone, AZA,
rituximab, natalizumab, IFN-beta, and IVIG. Treatment
responses varied considerably inter- and intraindividu-
ally. Patient 2 suffered from serious neurologic impair-
ment during the acute attack and during the following
months, but immunotherapy with IVMP, oral steroids,
PEX, and, for 12 months, IVIG was eventually followed
by almost complete remission and no more attacks.
Pathophysiologically, it is of interest that immunother-
apy and clinical recovery were paralleled by a significant
drop in MOG-IgG titers from 1:10,240 to 1:640 in this
patient. By contrast, IS/IM therapy was not effective in
preventing brainstem encephalitis in several other cases.
Of particular note, rituximab was followed by severe
clinical and radiologic deterioration with myelitis and
active (yet asymptomatic) lesions in the pons and me-
dulla oblongata within a few weeks after infusion in
patient 1, which is reminiscent of the possibly BAFF-
mediated deterioration reported in some NMO patients
after commencement of rituximab [64]. Moreover, a
massive brainstem attack with dysarthria, dysphagia, left
oculomotor and facial nerve palsy and new T2 lesions in
the pons, pedunculus cerebellaris, cerebral crus and
medulla oblongata occurred just 4 months after the last
rituximab infusion. In case 5, one brainstem attack took
place while the patient was being treated with AZA, one
during treatment with IFN-beta, and one 9 months after
commencement of natalizumab therapy. Patient 13 de-
veloped an attack of simultaneous myelitis and brain-
stem encephalitis four months after the first natalizumab
infusion and another one (with lesions in the medulla
oblongata) while on treatment with glatiramer acetate.
In case 7, a severe attack involving the brainstem, supra-
tentorial brain, and spinal cord occurred 4 weeks after
commencement of AZA treatment; similarly, patient 8
experienced several relapses, including a brainstem at-
tack, while on treatment with AZA. Of note, 14/34
relapes (in 10/17 AZA treated patients) were docu-
mented in the total cohort that took place during the
latency period of AZA (months 1-6) (see part 2 of this
series [17]). Of those, around 40 % occurred in patients
not co-treated with oral steroids during that period. This
suggests that co-treatment should be considered during
the latency period of AZA treatment in MOG-IgG-
positive patients, provided contraindications have been
excluded.
Disease exacerbation after IFN-beta
In common with other patients described in part 2 of
this series [17], patient 4 was initially diagnosed with
MS. Accordingly, she was treated with IFN-beta-1a i.m.
However, commencement of IFN-beta treatment was as-
sociated with marked disease exacerbation, characterized
by new brainstem and spinal cord lesions and a new
clinical attack. Similarly, patient 13 developed three
attacks of myelitis and/or optic neuritis while on treat-
ment with IFN-beta 1a i.m. or, later on, IFN-beta 1a s.c.
Disease exacerbation following IFN-beta administration
has also been reported in AQP4-IgG-positive NMO
[65–69] and likely reflects differences in the immuno-
pathogenesis of MS and NMO. This observation is of
high potential interest, since initial misdiagnosis as
classical MS – and, in consequence, mistreatment with
IFN-beta – might be even more common in MOG-IgG-
positive patients than in AQP4-IgG-positive patients
given the high rate of brain involvement in that condi-
tion [1]. Falsely classified AQP4-IgG- and, possibly, also
MOG-IgG-positive patients might account for some of
the occasional IFN-beta non-responders observed in MS
studies. Larger studies on the efficacy of IFN-beta in
MOG-IgG-positive patients treated with this substance
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in the past seem warranted, as does retrospective testing
for MOG-IgG of samples from IFN-beta non-responders
identified in past clinical trials.
Long-term prognosis differed widely but did not depend
on brainstem damage in most cases
Cases 1 and 2 illustrate that the prognosis differs widely
among MOG-IgG-positive patients: while brainstem en-
cephalitis led to respiratory insufficiency in both patients,
it was fatal in the former case and remitted almost
completely in the latter. Unexpectedly, residual neurologic
impairment in our patients was mostly not related to
brainstem damage. The median EDSS at last follow-up in
patients with a disease duration of >24 months (n = 12)
described here was 3 and ranged between 0 and 10;
only 4 patients had an EDSS >3 at last follow-up
(EDSS 4, 7.5, and 10 after 123, 225, and 507 months,
respectively).
Brainstem involvement was associated with a more
aggressive disease course
However, the median EDSS at last follow-up in pa-
tients with brainstem involvement and a disease dur-
ation of >24 months was still higher (median 3, range
0-10, n = 12) than among all patients from the total
cohort [17] who had no history of clinical or subclin-
ical brainstem involvement at last follow-up and an
observation time of ≥24 months (median EDSS 2; n = 23;
p < 0.04), as were the total number of attacks at last
follow-up (median 7.5, range 1-27, vs. median 3, range
1-28), the number of myelitis attacks (median 2, range
0-11, vs. median 0.5, range 0-3), the proportion of patients
who had experienced both attacks of ON and attacks of
myelitis at last follow up (75 % vs. 41.7 %), the median
annualized relapse rate (1.32 vs. 0.59, p < 0.03), and the
proportion of patients with additional supratentorial brain
lesions (75 % vs. 30.4 %; p < 0.02). As observation times
did not differ significantly between these two subgroups
(median 69.5, range 34-507, vs. median 70, range 26-394),
brainstem involvement seemed be a risk factor for a more
severe disease course. This has potential therapeutic im-
plications and should be addressed in future prospective
studies.
Limitations
We acknowledge some limitations of our study. Firstly,
the retrospective design is a potential limitation. How-
ever, prospective studies would be difficult to perform
due to the very low prevalence of the disease. Moreover,
reliable tests have become available only recently; ac-
cordingly, only retrospective long-term data are cur-
rently available. Furthermore, the number of patients
included and the number of items documented in the
present study were high and data loss relatively low.
Secondly, the multicenter design, which was necessary
given the low prevalence of the condition, could be a
limitation. However, the study design also strongly re-
duced the risk of selection bias, which was acknowl-
edged as a possible limitation by the authors of previous
large single-center studies in the field of NMO [30, 36].
Moreover, all patients were documented at university
centers providing a similar standard of tertiary care.
Thirdly, we cannot fully exclude a potential referral bias,
since MOG-IgG testing may have been ordered particu-
larly in patients presenting with ON and/or myelitis
based on the previous literature. It is therefore conceiv-
able that MOG-IgG-positive patients with isolated brain-
stem and/or brain involvement are underrepresented in
our study. Finally, from a pathophysiological point of
view it is a possible limitation that we cannot formally
prove that the antibody was already present at disease
onset in all cases, since routine MOG-IgG testing was
not available in the past. However, MOG-IgG was
present already at disease onset in all patients with avail-
able data in the main cohort, as reported in part 1 of this
series [3]: 2 MOG-IgG positive sera were taken within
the first week (at 2 and 4 days) after disease onset, 10
within the first month (median 10 days, range 2-31), and
18 within the first 3 months (median 26 days, range
2-85). The median MOG-IgG titer at disease onset was
1:2560 (range 160-20480; N = 18).
Conclusions
In summary, our study demonstrates that brainstem
involvement is common in patients with MOG-IgG-
related ON and/or myelitis. Our findings do not support
the notion that MOG-IgG seropositivity generally de-
notes a milder and usually monophasic variant of
NMOSD as suggested by earlier, smaller studies with
shorter observation periods. Most patients have a relaps-
ing general disease course, and serious and potentially
life-threatening complications of brainstem encephalitis
such as respiratory insufficiency may occur. This needs
to be kept in mind when deciding on long-term treat-
ment, and attention should be paid to signs or symp-
toms of additional brainstem involvement in patients
with MOG-IgG-positive ON and/or myelitis. Clinical
manifestations of MOG-IgG-positive brainstem enceph-
alitis are diverse and, notably, may include symptoms
previously thought to be typical for AQP4-IgG-positive
NMOSD, such as APS and INV, or of MS, such as
INO. In accordance with what was observed in the
total cohort [17], treatment with IVMP and/or PEX
was associated with good recovery in many cases. As
most MOG-IgG-positive patients develop relapses and
since brainstem involvement may indicate a more
aggressive disease course, prophylactic long-term
treatment should be considered in patients presenting
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with MOG-IgG-associated brainstem encephalitis. Larger
studies, which given the conditions’ relative rarity will
require an international collaborative approach, are
highly warranted to improve our understanding of the
full clinical spectrum, acute and long-term treatment
needs, and prognosis of MOG-IgG-related CNS disease
and in particular MOG-IgG-associated brainstem
encephalitis.
Appendix
Case 4 – Recurrent NMO starting with simultaneous
bilateral ON and LETM followed by an area postrema
syndrome; good partial recovery
In January 2012, a 30-year-old woman with no previous
personal or family history of autoimmune disease developed
sudden loss of vision and reduced visual field in the left eye
and 2 days later in the right eye, followed by tetraparesis
2 weeks later. While brain MRI showed no abnormalities,
spinal cord MRI revealed an LETM lesion extending from C2
to C7. The patient thus met Wingerchuk’s 2006 criteria for
NMO [35]. LP revealed CSF pleocytosis with 122 leukocytes/
μl (97 % mononuclear cells, 3 % granulocytes); OCB were not
determined. Treatment with IVMP was followed by partial
recovery. Four months later, a relapse of myelitis occurred in
the high cervical cord, now associated with brainstem
encephalitis. Symptoms included tetraparesis and INV. MRI
showed a brainstem lesion adjacent to the fourth ventricle
and including the area postrema, which continued into
the spinal cord. Brainstem symptoms completely remitted
2 months after IVMP treatment, and spinal symptoms
partially remitted with residual paresthesia and mild para-
plegia (BMRC 4+) after 3 months.
The patient subsequently had recurrent attacks of
isolated ON (3 × full recovery after IVMP) or isolated
myelitis (2 × full recovery after IVMP, 1 × partial recovery
after IVMP). Six of the eight attacks in this patient
occurred during 36 months of treatment with AZA, all
of them after discontinuation of co-treatment with oral
steroids (given for 3 months). At last follow-up, an EDSS
of 3 was documented. MOG-IgG was detected retro-
spectively in a sample taken during remission by means
of a live-cell CBA (1:640) and was confirmed by use of a
commercial fixed-cell CBA (Euroimmun). AQP4-IgG
was negative. The patient had no previous personal or
family history of autoimmune disease.
Case 5 – Recurrent ON, LETM and brainstem attacks, with
exacerbation after initiation of interferon-beta treatment;
high relapse rate
A 34-year-old Caucasian woman with a positive family
history for type 1 diabetes mellitus first presented with
paraparesis due to transverse myelitis in 10/2006, which
partially remitted after treatment with IVMP. Brain MRI
showed asymptomatic lesions adjacent to the lateral
ventricles. Five months later a second attack of
transverse myelitis with paraparesis occurred, again with
partial recovery after IVMP treatment; MR images from
that time are unavailable. Later the same year, the pa-
tient developed a first attack of unilateral ON. LP re-
vealed CSF pleocytosis but no CSF-restricted OCB.
Administration of IVMP was followed by partial recov-
ery. MS was suspected and treatment with intramuscular
interferon beta-1a (IFN-beta) was started. However,
3 months later she experienced a brainstem attack with
balance difficulties and vertigo. MRI revealed disease ex-
acerbation with new lesions in the pons and in the me-
dulla oblongata as well as multiple cervical and thoracic
spinal cord lesions. Symptoms remitted spontaneously.
In 01/2009 IFN-beta was discontinued and treatment
with natalizumab initiated. During the period of natali-
zumab treatment (03/2009 – 08/2010), one further at-
tack of brainstem encephalitis with impaired balance
and vertigo occurred. In 06/2010, follow-up spinal MRI
performed during remission demonstrated an LETM
lesion extending from T2 to T6. The findings on brain
MRI still did not meet the diagnostic criteria for MS. A
diagnosis of relapsing NMO according to Wingerchuk’s
2006 criteria [35] was made. Over the following
75 months, the patient experienced eight further attacks
of myelitis, one of ON, and one of brainstem encephalitis
with balance difficulties and dizziness. Four of these
episodes, including two of the myelitis attacks and the ON
attack (each with full remission after high-dose steroid
treatment) as well as the brainstem attack (complete spon-
taneous remission), occurred while the patient was being
treated with AZA for 36 months. Using a live-cell CBA,
low-titer MOG-IgG antibodies (1:160) were detected
retrospectively in a sample taken during remission. MOG-
IgG seropositivity was later confirmed in an independent
commercial fixed-cell CBA (Euroimmun). In addition,
low-titer serum IgA tissue transglutaminase antibodies
and antinuclear antibodies (ANA) were found. Serum
AQP4-IgG was negative. At last follow-up, an EDSS of 3
was documented.
Case 6 – ON followed by post-infectious LETM and
brainstem encephalitis 40 years later with poor outcome
At the age of 13 years this female patient had severe
unilateral ON (visual acuity 10 %) with complete remis-
sion. No further neurologic symptoms occurred for
40 years. At age 53 she developed subacute tetraparesis
and autonomic bladder and bowel dysfunction after a
severe bronchopulmonary infection and a prodromal
phase of diffuse tingling in all four extremities. She had
been previously diagnosed with rheumatoid arthritis
(RA) at the age of 43 years, and long-term treatment
with weekly methotrexate (MTX) had been initiated at
the age of 48 years. Due to the severe infection her
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immunosuppressive therapy had been stopped 4 weeks
before onset of the neurologic symptoms. Initial MRI
workup was inconclusive. Examination of CSF revealed
mild pleocytosis with 30 cells/μl and a disturbed BCSFB
function (QAlb 21.5) and no OCB. She was treated with
empirical antibiotics and aciclovir. As the clinical pres-
entation worsened, the patient became bedridden and
lost bladder and bowel control. MRI was repeated and
now revealed a longitudinally extensive spinal cord le-
sion extending centrally from the medulla oblongata to
the mid-thoracic level with patchy Gd enhancement;
brain MRI revealed no other abnormalities. No symp-
toms attributable to the medulla oblongata lesion were
present. High-dose steroid treatment was initiated and
was followed by 5 cycles of therapeutic PEX. She was
restarted on her immunosuppressive treatment with
MTX and recovered rapidly but only partially. At last
follow-up, 1.5 years after this episode, she is ambulatory
with no motor deficits but still reports painful
dysesthesia and is restricted by severe sensory gait ataxia
(EDSS 6.5). Anti-MOG antibodies were retrospectively
assessed and found positive in a live-cell CBA of stored
serum samples obtained between steroid treatment and
the commencement of therapeutic PEX (1:2560) and at
a follow-up visit (1:160); both samples were also positive
in the fixed-cell CBA. AQP4-antibodies were negative in
several samples.
Case 7 – Recurrent LETM and subclinical ON with
extensive brainstem and brain involvement; almost full
recovery
A Caucasian man experienced a first attack of myeli-
tis with marked paraparesis in February 2012 at the
age of 19; this episode remitted fully after IVMP
therapy. Spinal cord MRI showed a transverse inflam-
matory lesion at T9/10 with swelling and Gd en-
hancement. Brain MRI detected no abnormalities. LP
revealed CSF-restricted OCB. Another attack of mye-
litis with hypesthesia of both legs occurred in May
2012. MRI showed enlargement of the known thoracic
lesion, now spanning from T8 to T12, again with
swelling and Gd enhancement. At that time, pro-
longed P100 latency (but with normal amplitudes)
was noted on the left side (visual acuity [VA] 0.95 in
both eyes). IVMP therapy was again followed by
complete remission. AQP4 antibodies were negative,
but NMO was suspected and, therefore, treatment
with AZA started. A few weeks later, the patient de-
veloped severe headache, diplopia, and gait ataxia.
MRI performed several times over a period of 4 weeks
showed evolving confluent T2-hyperintense lesions in
the right temporal lobe, lesions in the periaqueductal
grey, the pulvinar bilaterally, and the ventral pons, as
well as cervical lesions at C6/7 and an LETM lesion
extending from T8 to the conus with Gd enhance-
ment. LP revealed an elevated cell count (22/μl), total
CSF protein of 460 mg/l, and positive OCB. VEP
showed increased P100 latency on both sides and
normal amplitudes. The clinical deficits remitted only
partially after one course of IVMP and after thera-
peutic PEX (five exchanges). B-cell-depleting therapy
with rituximab was started in August 2012 and was
followed by further slow resolution of symptoms. In
May 2013, after repopulation of B cells, mild ON in
the right eye occurred but remitted spontaneously. Ri-
tuximab therapy was resumed and the patient
remained free of disease activity with minor deficits
(EDSS of 1.0) until last follow-up in December 2014.
MOG-IgG were retrospectively tested using a live-cell
CBA and were positive at a titer of 1:1280.
Case 8 – Post-vaccination myelitis and recurrent ON with
brainstem and brain involvement; full recovery
A 19-year-old male patient presented with headache,
meningism, and photophobia. The patient had received a
vaccination (diphtheria, tetanus, pertussis, polio; and
influenza) 2 weeks before symptom onset. Examination of
the CSF revealed pleocytosis (43 cells/μl; predominantly
lymphomonocytic, 3.1 % neutrophils). Brain MRI demon-
strated multiple T2 hyperintensities in the pulvinar thalami
bilaterally and in the rostral putamen as well as leptomen-
ingeal contrast enhancement. Spinal MRI revealed a lesion
at C1 and another one extending from T11 to T12.
Pragmatic treatment with ceftriaxone, ampicillin, and
acyclovir was started, together with IVMP. After clinical
recovery, the patient was discharged to a rehabilitation fa-
cility with the diagnosis of suspected viral meningoence-
phalomyelitis of undetermined origin. However, 1 month
later he was readmitted with disorientation, headache,
meningism, fever, and fatigue. CSF analysis again revealed
pleocytosis (60 white cells/μL; 26 % neutrophils). Brain
MRI demonstrated T2-hyperintense lesions in the mid-
brain, pons, thalamus, basal ganglia, and corpus callosum.
Lesions involved the periependymal surfaces of the third
ventricle. Spinal cord MRI showed a contrast-enhancing le-
sion at C5. Shortly thereafter, the patient developed prox-
imal spastic paraparesis, urinary retention, and bilateral
visual deficits, accompanied by delayed P100 latencies,
MRI-detectable lesions involving the optic chiasm and
both optic tracts, and a new T2 hyperintensity at C3.
MOG-IgG were positive at a titer of 1:2560. AQP4
antibodies were negative. Treatment with IVMP (1 g/d
for 5 days) followed by 5 cycles of PEX led to full clinical
and neuroradiologic recovery within 3 months. Long-term
immunosuppressive treatment with AZA was initiated.
Within the following 20 months, four further attacks of
ON (ranging from mild to severe) and presumably
one further attack of brainstem encephalitis with
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hearing loss occurred, with each showing full remis-
sion after high-dose steroid treatment (EDSS 0 at last
follow-up).
Case 9 – Recurrent ON with subclinical brainstem and
spinal cord involvement; almost full recovery
In December 2014, 4 weeks after an ENT infection, a 50-
year-old Caucasian man developed a first, left-sided ON
(blurred vision, retro-orbital pain, VA OS 30 %, P100 OS
delayed) which remitted almost completely after treatment
with IVMP. Neurologic examination was otherwise unre-
vealing except for slightly increased tendon reflexes, in par-
ticular of the lower extremities. Brain MRI showed an
asymptomatic, median pontine lesion without Gd enhance-
ment; in addition, there was inflammation of the entire optic
nerve and parts of its sheath, with extensive Gd enhance-
ment and subtle swelling compared with the other side.
Spinal cord MRI demonstrated a possible lesion at C6/7. LP
was unrevealing (negative OCB, no pleocytosis, no BCSFB
dysfunction). Infectious causes of ON were excluded.
Serologically, there was no indication of vasculitis. MOG-
IgG antibodies were found to be positive at that time. Due
to flaring up of the ON shortly after, the pulse therapy was
repeated with 5 × 2 g IVMP, which had no effect. By con-
trast, PEX treatment (8 cycles) starting 10 days after the last
IVMP dose resulted in almost complete recovery.
However, 2 months later a relapse of unilateral ON of
the left eye occurred with complete visual loss (VA OS
0 %; Snellen chart), impaired color vision, and retro-
orbital pain. Brain MRI showed inflammation of the
posterior (pre-chiasmal) part of the optic nerve with Gd
enhancement but no significant swelling. Standard VEP
findings had worsened (P100 not detectable in left eye);
flash VEP revealed a marked P100 prolongation and
reduced amplitudes in the left eye. While the pontine
lesion had markedly decreased in size, several new dorso-
lateral and central spinal cord lesions without Gd en-
hancement had developed (T7/8, T8/9 and T11/12).
MOG-IgG were positive at a titer of 1:10,240. PEX
treatment (8 cycles) led to almost full clinical recovery,
with discretely disturbed color vision and an increased
sensitivity to glare as residual symptoms. Standard VEP
also improved following PEX treatment, but still showed a
delay in latency (159 ms) and reduced amplitudes
compared with the right eye. Treatment with rituximab
was commenced without complications. At last follow-up
(May 2015) the patient had almost fully recovered (VA OS
0.9; EDSS 1.5).
Case 10 – Protracted and recurrent ON with complete
visual loss and signs of mild myelitis and brainstem
encephalitis; complete recovery
A previously healthy 37-year-old man presented with a
4-day history of bifrontal headache, pain upon eye
movement, and bilateral complete visual loss and color
desaturation. Ophthalmoscopy revealed bilateral papille-
dema. Markedly prolonged P100 latencies were noted in
both eyes, suggestive of demyelination. Brain MRI showed
a bilateral optic nerve lesion with swelling and Gd en-
hancement but did not reveal any brain lesions. Spinal
cord MRI was normal. Serum AQP4-IgG was negative, as
were CRP, ANA, ANCA, rheumatoid factor, lupus coagu-
lant, anti-gliadin and anti-transglutaminase, HIV, HTLV-1,
and vitamin B12. CSF examination demonstrated mild
pleocytosis (5 cells/μl; including 34 % neutrophils and 6 %
eosinophils) and identical OCB in CSF and serum but was
otherwise normal (including a negative MRZ reaction).
Treatment with IVMP (1 g/d for 5 days) was followed by
marked improvement in VA. However, only 4 days later
the patient was readmitted with new visual impairment;
scotoma; hypesthesia of the right lower face and nose, the
right hand, and the lateral parts of the right arm;
paresthesia in the fingers of both hands and in both legs;
and headache. No repeat MRI was performed. VEP and
SSEP were normal. AQP4-IgG was still negative. Repeat
LP revealed a mild lymphomonocytic pleocytosis (8 cells/
μl). The patient’s visual deficits increased (0.6 OS, 0.8 OD)
despite a second, prolonged IVMP cycle (1 g/d for 7 days);
symptoms stabilized (but did not improve) after PEX (five
exchanges). Two days after discharge the patient was again
readmitted with further decrease in VA in the left eye
(0.3), marked bilateral scotoma (OS> >OD), headache
(NAS 3), and vertigo (“like in an elevator moving down”).
VEP showed a further increase in P100 latency in the left
eye. Treatment with IVMP was followed by complete
remission (VA 1.0 in both eyes at discharge). However,
follow-up VEP still showed markedly delayed, albeit
slightly improved, P100 latencies in both eyes (154 ms
compared to 178 ms at previous examination). To prevent
further flare-ups after steroid withdrawal, treatment with
oral steroids (100 mg/d; tapering to 10 mg/day) was
initiated and, taking into consideration the patient’s
positive MOG-IgG serostatus, long-term treatment
with AZA started. At follow-up 63 days after onset,
the patient reported persisting color desaturation and
impaired contrast perception, together with paresthesia in
the left leg. The patient discontinued AZA after two
months.
Six months after onset and one month after the first
infusion of rituximab (1000 mg), he developed a relapse
of ON, which fully responded to high-dose IVMP treat-
ment, another infusion of rituximab (1000 mg) and
subsequent oral steroid treatment. Another two months
later, shortly after oral steroids were tapered out, a third
attack of ON occurred, which was associated with mild
hemiparesis and hemihypesthesia, which fully remitted
following treatment with IVMP and, subsequently, oral
steroids.
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Case 11 – Myelitis and recurrent ON with lesions in the
cerebellar peduncle and the frontal lobe; partial remission
A previously healthy 44-year-old Caucasian woman pre-
sented in February 2011 with sensorimotor paraparesis and
urinary incontinence. Spinal MRI showed a cervicothoracic,
longitudinally extensive spinal cord lesion with patchy Gd
enhancement and further short, patchy spinal cord lesions.
Brain MRI revealed a lesion in the cerebellar peduncle and
one small cerebral lesion located in the left frontal lobe with
slight Gd enhancement. The myelitis symptoms partially
recovered under IVMP (1 g/d for 5 days) with residual de-
trusor sphincter dyssynergy and slight gait ataxia. Subse-
quently, the patient suffered recurrent urinary tract
infections, which were effectively controlled by use of me-
thionine (3 × 500 mg/d). In May 2011 she developed vision
loss in the right eye (VA 0.2) with prolonged P100 latency
and reduced P100 amplitudes. VA recovered to 0.75 after
IVMP therapy within two months. Two months later, the
patient experienced an attack of ON in the previously un-
affected left eye (VA reduced to light perception). Partial re-
mission was achieved after 5 PEX cycles; previous treatment
with IVMP for 5 days had not resulted in any improvement.
In August 2011, immunosuppressive treatment with mitox-
antrone was started (10 mg/m2; 4 cycles at 6-week intervals;
no relapses). In January 2012, therapy was switched to AZA
(2 mg/kg). After at least three attacks of unilateral ON
under AZA, the patient’s treatment was changed to rituxi-
mab (1000 mg i.v. in February 2015 and March 2015,
respectively). Complete B cell suppression was noted
3 months after treatment. In June 2015 she developed
bilateral ON with VA of 0.2 in the right eye and 0.05
in the left eye. After IVMP (5 g) and five cycles of
PEX, VA improved. At the time of her last follow-up
visit in August 2015, VA was 0.8 in both eyes and an
EDSS of 2.5 was documented.
Case 12 – Simultaneous ON and LETM with post-partum
onset and pontomedullary brainstem encephalitis; full
recovery
A 27-year-old woman developed a first, painful attack of
ON in July 2012, just 6 weeks after the delivery of her first
child. Ophthalmologic assessment revealed VA of 0.8,
papilledema, and delayed VEP latencies (but normal
amplitudes) in the left eye. Cranial MRI showed swelling
as well as intraneural and perineural contrast enhance-
ment extending over the anterior two thirds of the left
optic nerve but was otherwise unremarkable. The CSF
had normal cell and protein profiles with negative OCB.
High-dose intravenous pulse therapy with IVMP
(1000 mg/d for 3 days) was followed by complete reso-
lution of symptoms. However, a few days later (and
2 weeks after attack onset) the patient noticed right-sided
ocular pain upon eye movements, diplopia, paresthesia
around her mouth and her waist, and urge incontinence.
On neurologic examination she had a left-sided sixth
nerve palsy, gaze-directed horizontal and vertical nystag-
mus, and a mildly unsteady gait. VA was normal. MRI of
the brain and spinal cord now revealed T2-hyperintense
lesions extending from the pontomedullary junction
throughout the cervical cord as far as C5 as well as an
additional T2 hyperintensity located in the juxtacortical
insular region on the left side. None of these abnormalities
showed Gd enhancement. Repeat lumbar puncture dis-
closed lymphocytic pleocytosis (59 cells/μl) in the pres-
ence of normal lactate and protein levels, including
negative OCB. Antineuronal and AQP4 antibodies were
negative and there was no evidence of an infectious eti-
ology. The patient was treated with IVMP (1000 mg daily
for 5 days) followed by 80 mg orally with subsequent ta-
pering for 7 weeks.
In September 2012, at a maintenance dose of 5 mg
methylprednisolone per day and after improvement of
symptoms, she experienced right-sided ON leading to a
moderate decline in visual acuity (0.6). She received a fur-
ther course of IVMP (1000 mg daily for 3 days) and oral
therapy with decreasing doses of prednisolone (starting
with 80 mg) for a total of 4 weeks with a permanent main-
tenance dose of 10 mg daily. This regimen prompted
normalization of visual impairment. AQP4-IgG, tested in
a CBA, was again negative. Long-term treatment with
AZA and oral corticosteroids was started.
In October 2012 (6 weeks after onset of the last attack),
just 4 days after termination of steroid therapy and 1 day
following reduction of AZA from 150 mg to 100 mg daily
because of elevated liver enzymes, the patient developed a
third episode of painful ON with right-sided visual impair-
ment. She received another course of 1000 mg IVMP daily
for 5 days followed by oral tapering, which resulted in
complete recovery. AZA was stopped in November 2012
and replaced by MTX in February 2013. The patient dis-
continued MTX in November 2014 because she wanted a
second pregnancy. At that time, MRI showed mild residual
signal hyperintensity in the left optic nerve, no brain
lesions, and a residual short spinal T2 hyperintensity at the
C4/5 level. At last follow-up in 09/2015, she had not
experience new neurologic symptoms (EDSS 0). Three
stored sera obtained in July 2012 were retrospectively tested
positive for MOG-IgG at a titer of 1:5120 each.
Case 13 – Recurrent ON and myelitis; hypesthesia of the
tongue and cheek; lesions in the medulla oblongata and
in the pons; ongoing disease activity during treatment
with IFN-beta and GLAT
A 19-year old woman developed acute hypesthesia of
both hands and Lhermitte’s sign in 2007. Fifteen months
before that event, she had suffered from an episode of
extremely painful headache starting 4 weeks after influ-
enza vaccination and lasting for 14 days (no previous
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history of headache). Brain MRI was normal at the time
of attack onset, but spinal cord MRI revealed a single le-
sion at C2. CSF examination demonstrated lymphocytic
pleocytosis (33 cells/μl) and intrathecal IgG and IgM
synthesis. VEP, SSEP and MEP were normal. Two
months later, she developed unilateral ON. Both attacks
were treated with IVMP, which was followed by
complete recovery in each case. Over the following
8 years, she developed at least seven more attacks of
myelitis and two more attacks of ON despite immuno-
modulatory or immunosuppressive treatment with IFN-
beta 1a s.c., IFN-beta 1a i.m., GLAT, natalizumab or fin-
golimod for suspected MS, with partial or full recovery
following steroid treatment. While most myelitis attacks
were characterized by sensory symptoms (including
girdle-like or, later, generalized dysesthesia and pain),
some resulted in spastic paresis of the lower extremities
and impaired ambulation requiring unilateral assistance.
Repeat MRI demonstrated both short spinal cord lesions
and LETM lesions, partly with swelling of the spinal
cord and contrast enhancement. ON attacks were mostly
mild, but severe attacks occurred as well (VA 0.25, per-
ipheral scotomas). At least twice, she experienced simul-
taneous ON and myelitis. Several repeat brain MRIs
showed (partly contrast-enhancing) juxtacortical, deep
white matter, callosal, and periventricular lesions. While
the initial LP had revealed quantitative evidence for intra-
thecal synthesis of both IgG (33 % of total CSF IgG) and
IgM (59 % of total CSF IgM), only intrathecal IgG synthe-
sis was detected at repeat LP during another acute an
acute attack 10 months later. Nineteen months after on-
set, she developed an attack of myelitis with hypesthesia
in both legs, Lhermitte’s sign, and lesions at C2, C6, and
C7 which was accompanied by hypesthesia of the tongue
and facial hypesthesia, dysesthesia and pain, suggesting
brainstem encephalitis. However, no brainstem MRI was
performed at that time. Two follow-up MRIs showed T2-
hyperintense, non-contrast enhancing lesions in the me-
dulla oblongata and in the pons, which remained detect-
able over a period of at least once year. Additional
symptoms attributable to brainstem lesions included im-
paired coordination, impaired ambulation, and disturbed
smooth pursuit. Microbiological examinations for Borrelia
burgdoferi, HIV, HBV, HCV and VZV as well as serological
examinations for rheumatic diseases were negative. At last
follow-up in 2016, an EDSS score of 3.5 was documented.
Case 14 – LETM with pontomedullary brainstem
encephalitis and relapsing ON; almost full recovery
A female Caucasian patient developed a first attack of
unilateral ON at the age of 17 but recovered fully after
IVMP treatment. Brain MRI was normal at onset. CSF
examination revealed mild pleocytosis (8 cells/μl) and
evidence of BCSFB dysfunction but not of intrathecal
IgG synthesis. Seven months later, she developed
paraparesis due to an attack of acute myelitis; IVMP
treatment was followed by complete recovery. Over the
next 56 months, five further attacks of ON occurred
(three while on GLAT for suspected MS, one with tran-
sient unilateral blindness several weeks after GLAT had
been discontinued due to an unplanned pregnancy, and
one after 8 months of AZA treatment), all of which
responded to IVMP therapy, as well as two further
attacks of non-longitudinally extensive transverse myeli-
tis, one of which was associated with internuclear
ophthalmoplegia (INO). The latter attack occurred
under treatment with IVIG. Previously, AZA had had to
be discontinued due to an increase in liver enzymes and
a planned pregnancy. During that attack, brain MRI
showed a large, Gd-enhancing brainstem lesion affecting
the pons bilaterally, both pedunculi cerebelli, and the
paramedian pontomedullary junction. Spinal cord MRI
showed two separate lesions at C2/3 and C5. In addition,
Gd-enhancing supratentorial lesions located peritrigon-
ally and in the corona radiata were noted. PEX was
required in addition to IVMP to achieve remission of
symptoms. Treatment with rituximab had to be stopped
after the first infusion due to an allergic skin reaction.
Under subsequent immunosuppression with ofatumumab
(18 months so far, 4 cycles) one additional ON attack has
occurred (14 months after commencement of therapy).
Despite the high number of nine ON attacks and
complete blindness during one of those attacks, the pa-
tient had almost normal VA (0.9) at last FU. VEP showed
prolonged P100 latencies and reduced amplitudes.
Case 15 – Hemihypesthesia including the face; bilateral
lesion in the pons and the cerebellar peduncles; myelitis;
partial recovery
This 25-year-old Caucasian woman first presented in
February 2016 with tingling paresthesias of her left arm
and leg, which had developed over the course of 2 days.
She had a history of asthma bronchiale and neurodermi-
tis, but except for a bipolar disorder and rare attacks of
typical migraine no history of neurological symptoms.
She had suffered from fever and fatigue 2 weeks before
her neurological symptoms started. Neurological exam-
ination revealed paramedian moderate left-sided tactile
hemihypesthesia including the face and a pathologically
increased left knee-jerk without other pyramidal signs,
as well as an unstable Romberg stance with eyes closed,
but was otherwise unremarkable. In particular she had
no limb ataxia and no further cerebellar signs. Auto-
immune serology revealed a strongly increased ANA
titer of 1:320 with a speckled/spindle apparatus staining
pattern, while no ENA antibodies and no ANCA were
detectable. Cranial MRI revealed bilateral lesions of the
pons, more marked on the right side, and bilateral
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lesions in the cerebellar peduncles as well as a single
small lesion directly adjacent to the left lateral ventricle,
while MRI of the whole spinal cord showed no abnor-
malities. CSF analysis revealed pleocytosis (150 white
cells/μl; 29 % lymphocytes, 45 % monocytes, 26 % granu-
locytes), total protein of 56.1 mg/dl (<50), and an in-
creased albumin quotient of 11.3 (upper limit of age-
corrected normal = 7.0); isoelectric focusing revealed
identical OCB in serum and CSF; no intrathecal anti-
body synthesis against measles, rubella, varicella zoster,
and herpes simplex virus was detectable. CSF PCR ana-
lyses of a panel of neurotropic viruses were negative.
Serology of serum and CSF was negative for Lyme
disease and syphilis. Visual, sensory, and motor evoked
potentials were normal. Owing to the history of recent
fever and CSF pleocytosis including neutrophils, treat-
ment with aciclovir i. v. and ceftriaxone was started,
based on a tentative diagnosis of infectious, primarily
viral encephalitis on the day of admission. Aciclovir was
discontinued after negative viral PCR results became
available, while ceftriaxone was continued for 14 days.
After an initial worsening of the patient’s hemihypesthe-
sia, occurrence of a mild left-sided hemiparesis, and
newly occurring intermittent urinary hesitancy over a
few days, the symptoms started to gradually improve.
Another lumbar puncture 14 days after admission re-
vealed a cell count of 98/μl. The patient was discharged
with partial relief of symptoms. Positive anti-MOG IgG
and negative aquaporin-4 antibody results arrived after
discharge.
Four weeks later the patient was again admitted to our
department with new sensory disturbances affecting her
trunk and legs below T10 and stance and gait ataxia.
MRI now revealed a lateral spinal cord lesion spanning
from T8 to T9 without contrast enhancement. Another
spinal tap showed pleocytosis (20 white cells/μl), a now
normal albumin quotient of 5.6, and again identical
OCB in serum and CSF. Flow cytometric CSF analysis
revealed 10 % lymphocytes, all CD3-positive, and a
marginally increased CD4/CD8 ratio of 4.4. Visual and
sensory evoked potentials were again normal, while the
patient rejected analysis of motor evoked potentials.
Treatment with IVMP (5 × 1 g/day) induced partial re-
mission of her new symptoms. Cranial MRI after steroid
initiation revealed moderate regression of all known
brain lesions and no new lesions. After a well-tolerated
test dose, secondary prophylactic treatment with azathi-
oprine 150 mg/day was started.
The patient next attended our neuroimmunological
outpatient clinic for a routine follow-up appointment in
June 2016. She reported that the residual left-sided
sensorimotor symptoms from her first attack had inten-
sified in the previous 4 weeks, indicating a potential
mild relapse. Two weeks before the beginning of this
intensification of symptoms she had had a feverish re-
spiratory infection, for which she had received antibiotic
treatment. Based on a peripheral blood lymphocyte
count of 2470/μl, the azathioprine dose was increased.
An EDSS of 3 was documented.
Abbreviations
AQP4: aquaporin-4; AZA: azathioprine; BCSFB: blood-CSF barrier; BMRC: British
Medical Research Council; CSF: cerebrospinal fluid; EDSS: expanded disability
status scale; GLAT: glatiramer acetate; IFN-beta: interferon-beta;
IgG: immunoglobulin G; IM: immunomodulatory; IS: immunosuppressive;
IVIG: intravenous immunoglobulins; IVMP: intravenous methylprednisolone;
LETM: longitudinally extensive transverse myelitis; LP: lumbar puncture;
MOG: myelin oligodendrocyte glycoprotein; MRI: magnetic resonance
imaging; MS: multiple sclerosis; MTX: methotrexate; NMO: neuromyelitis
optica; NMOSD: neuromyelitis optica spectrum disorder; OCB: oligoclonal
bands; ON: optic neuritis; QAlb: albumin CSF/serum quotient; RA: rheumatoid
arthritis; SSEP: somatosensory evoked potentials; VA: visual acuity; VEP: visual
evoked potentials
Acknowledgments
BW and SJ are grateful to the Dietmar Hopp Foundation and to Merck
Serono for funding research on NMO and related disorders at the Molecular
Neuroimmunology Group, Department of Neurology, University of
Heidelberg, and to Mrs. Anna Eschlbeck and the Nikon Imaging Center at
the University of Heidelberg for excellent technical assistance. FrP would like
to acknowledge research support by the German Research Council (DFG Exc
257) and by the Federal Ministry for Education and Research (Competence
Network Multiple Sclerosis). MRe would like to thank the Eugene Devic
European Network (EDEN) project (ERA–Net ERARE 2; Austrian Science Fund
FWF project I916) and the Austrian Federal Ministry of Science, Research and
Economy (grant Big Wig MS).
Funding
The work of BW was supported by research grants from the Dietmar Hopp
Stiftung and from Merck Serono. The work of FrP, KR, and OA was supported
by the German Federal Ministry of Education and Research (BMBF/KKNMS,
Competence Network Multiple Sclerosis). FrP was supported by the German
Research Foundation (DFG EXC 257). MRe was supported by the Austrian
Federal Ministry of Science, Research and Economy (grant Big Wig MS) and
the Eugene Devic European Network (EDEN) project (ERA–Net ERARE 2;
Austrian Science Fund FWF project I916).
Availability of data and materials
The datasets generated during and/or analysed during the current study are
not publicly available due to local data protection requirements but are
available from the corresponding author on reasonable request in an
anonymized fashion.
Authors’ contributions
SJ, BW, MRe and FrP conceived the study. SJ designed the study, collected
the data, created the database software, analysed the data, and wrote the
manuscript. MRe and KS performed the live-cell CBA. SJ and KF performed
the fixed-cell CBA. All other authors collected clinical and paraclinical data,
were involved in patient care, and/or have contributed case reports. All
authors were involved in revising the manuscript for intellectual content.
All authors read and approved the final draft before submission.
Competing interests
BW has received research grants, speaking fees, and travel grants from Merck
Serono, Biogen, Teva, Novartis, Sanofi Genzyme, Bayer Healthcare, Biotest,
and the Dietmar Hopp Stiftung. KR has received research support from
Novartis as well as speaking fees and travel grants from Guthy Jackson
Charitable Foundation, Bayer Healthcare, Biogen Idec, Merck Serono, Sanofi/
Genzyme, Teva, Roche, and Novartis, none of which is related to the present
study. OA has been supported by the Walter and Ilse Rose Foundation. IK
has received travel cost reimbursements or speaker or consulting honoraria
from Bayer Healthcare, Biogen-Idec, Novartis, and Chugai as well as research
support from Bayer Healthcare, Biogen-Idec, Chugai, Diamed, and Novartis,
none related to this study. FrP has received research support from Bayer,
Jarius et al. Journal of Neuroinflammation  (2016) 13:281 Page 21 of 23
Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Merck Serono, Alexion,
Chugai, Arthur Arnstein Stifung Berlin, Guthy Jackson Charitable Foundation,
and the US National Multiple Sclerosis Society; has received travel funding
and/or speaker honoraria from Bayer, Novartis, Biogen Idec, Teva, SanofiAventis/
Genzyme, and Merck Serono; and has consulted for Sanofi Genzyme, Biogen
Idec, and MedImmune; none of which is related to the present paper. KF is an
employee of Euroimmun AG, Lübeck, Germany. MRi has received speaker
honoraria from Novartis and Bayer Vital GmbH and travel cost reimbursement
from Bayer Schering, Biogen Idec, Genzyme, and the Guthy Jackson Charitable
Foundation, none related to this study. The Medical University of Innsbruck and
University Hospital Innsbruck (MRe and KS) has received payments for
antibody assays (aquaporin-4 and other anti-neuronal and anti-glial
antibodies) and for aquaporin-4 antibody validation assays organized by
Euroimmun (Lübeck, Germany) not related to the present study. CT has
received honoraria for consultation and expert testimony as well as travel
grants from Bayer Vital GmbH, Biogen Idec, Genzyme GmbH, Fresenius
Medical Care, Novartis Pharmaceuticals, Sanofi Aventis Deutschland
GmbH, and Teva Pharma GmbH; none of these related to the current
study. The other authors report no competing interests.
Consent for publication
Participants gave written informed consent for publication of their clinical
and paraclinical data.
Ethics approval and consent to participate
The study was approved by the review boards of the participating centers
and patients gave written informed consent.
Author details
1Molecular Neuroimmunology Group, Department of Neurology, University
Hospital Heidelberg, Otto Meyerhof Center, Im Neuenheimer Feld 350, 69120
Heidelberg, Germany. 2Department of Neurology, Ruhr University Bochum,
Bochum, Germany. 3Department of Neurology, Charité – University Medicine
Berlin, Berlin, Germany. 4Department of Neurology and Institute of Molecular
Medicine, University of Southern Denmark, Odense, Denmark. 5Department
of Neurology, Hannover Medical School, Hannover, Germany. 6Department
of Neurology, NeuroCure Clinical Research Center and Clinical and
Experimental Multiple Sclerosis Research Center, Charité University Medicine,
Berlin, Germany. 7Experimental and Clinical Research Center, Max Delbrueck
Center for Molecular Medicine, Berlin, Germany. 8Department of Neurology,
University of Rostock, Rostock, Germany. 9Department of Neurology, Albert
Ludwigs University, Freiburg, Germany. 10Department of Neurology, Heinrich
Heine University, Düsseldorf, Germany. 11Department of Neuroradiology,
Ruhr University Bochum, Bochum, Germany. 12Institute of Experimental
Immunology, affiliated to Euroimmun AG, Lübeck, Germany. 13Department of
Neurology, Julius Maximilians University, Würzburg, Germany. 14IRCCS, C.
Mondino National Neurological Institute, Pavia, Italy. 15Department of
Neurology, Medical University Innsbruck, Innsbruck, Austria.
Received: 1 April 2016 Accepted: 9 September 2016
References
1. Reindl M, Di Pauli F, Rostasy K, Berger T. The spectrum of MOG autoantibody-
associated demyelinating diseases. Nat Rev Neurol. 2013;9:455–61.
2. Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, Lutterotti A,
Jarius S, Di Pauli F, Kuenz B, et al. Complement activating antibodies to
myelin oligodendrocyte glycoprotein in neuromyelitis optica and related
disorders. J Neuroinflammation. 2011;8:184.
3. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O,
Beume L, Hümmert MW, et al. MOG-IgG in NMO and related disorders: a
multicenter study of 50 patients. Part 1: Frequency, syndrome specificity,
influence of disease activity, long-term course, association with AQP4-IgG, and
origin. J Neuroinflammation. 2016. doi:10.1186/s12974-016-0717-1.
4. Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, Palace J,
Vincent A. Myelin-oligodendrocyte glycoprotein antibodies in adults with a
neuromyelitis optica phenotype. Neurology. 2012;79:1273–7.
5. Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, Kuker W,
Chandratre S, Vincent A, Palace J. Neuromyelitis optica spectrum disorders
with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a
comparative study. JAMA Neurol. 2014;71:276–83.
6. Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM,
Takahashi T, Nakashima I, Apostolos-Pereira SL, Talim N, Simm RF, et al.
Distinction between MOG antibody-positive and AQP4 antibody-positive
NMO spectrum disorders. Neurology. 2014;82:474–81.
7. Probstel AK, Rudolf G, Dornmair K, Collongues N, Chanson JB, Sanderson
NS, Lindberg RL, Kappos L, de Seze J, Derfuss T. Anti-MOG antibodies are
present in a subgroup of patients with a neuromyelitis optica phenotype.
J Neuroinflammation. 2015;12:46.
8. Nakajima H, Motomura M, Tanaka K, Fujikawa A, Nakata R, Maeda Y, Shima T,
Mukaino A, Yoshimura S, Miyazaki T, et al. Antibodies to myelin oligodendrocyte
glycoprotein in idiopathic optic neuritis. BMJ Open. 2015;5:e007766.
9. Waters P, Woodhall M, O’Connor KC, Reindl M, Lang B, Sato DK, Jurynczyk
M, Tackley G, Rocha J, Takahashi T, et al. MOG cell-based assay detects
non-MS patients with inflammatory neurologic disease. Neurol
Neuroimmunol Neuroinflamm. 2015;2:e89.
10. van Pelt ED, Wong YY, Ketelslegers IA, Hamann D, Hintzen RQ. Neuromyelitis
optica spectrum disorders: comparison of clinical and magnetic resonance
imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the
Netherlands. Eur J Neurol. 2016;23:580–7.
11. Konig FB, Wildemann B, Nessler S, Zhou D, Hemmer B, Metz I, Hartung HP,
Kieseier BC, Bruck W. Persistence of immunopathological and radiological
traits in multiple sclerosis. Arch Neurol. 2008;65:1527–32.
12. Jarius S, Metz I, König F, Ruprecht K, Reindl M, Paul F, Brück W, Wildemann
B. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal
autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a
MOG-IgG-positive case. Mult Scler. doi:10.1177/1352458515622986.
13. Spadaro M, Gerdes LA, Mayer MC, Ertl-Wagner B, Laurent S, Krumbholz M,
Breithaupt C, Hogen T, Straube A, Giese A, et al. Histopathology and clinical
course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl
Neurol. 2015;2:295–301.
14. Saadoun S, Waters P, Owens GP, Bennett JL, Vincent A, Papadopoulos MC.
Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain.
Acta Neuropathol Commun. 2014;2:35.
15. Wingerchuk D, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J,
Fujihara K, Greenberg B, Jacob A, et al. International Consensus Diagnostic
Criteria for Neuromyelitis Optica Spectrum Disorders. Neurology 2015;85:177–89.
16. Sven Jarius, Brigitte Wildemann. The history of neuromyelitis optica.
J Neuroinflammation. 2013;10:8.
17. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O,
Beume L, Hümmert MW, et al. MOG-IgG in NMO and related disorders: a
multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation,
radiological and laboratory features, treatment responses, and long-term
outcome. J Neuroinflammation. 2016. doi:10.1186/s12974-016-0718-0
18. Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC,
Bellmann-Strobl J, Jarius S, Wildemann B, Reindl M, et al. MOG-IgG in NMO
and related disorders: a multicenter study of 50 patients. Part 4: Afferent
visual system damage after optic neuritis in MOG-IgG-seropositive versus
AQP4-IgG-seropositive patients. J Neuroinflammation. 2016. doi:10.1186/
s12974-016-0720-6.
19. Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N,
Kleiter I, Aktas O, Kumpfel T. Update on the diagnosis and treatment of
neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study
Group (NEMOS). J Neurol. 2013;261:1–16.
20. Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, Kleiter
I, Kleinschnitz C, Berthele A, Brettschneider J, et al. Contrasting disease
patterns in seropositive and seronegative neuromyelitis optica: A
multicentre study of 175 patients. J Neuroinflammation. 2012;9:14.
21. Ayzenberg I, Schöllhammer J, Hoepner R, Hellwig K, Ringelstein M, Aktas O,
Kümpfel T, Krumbholz M, Trebst C, Paul F, et al. Efficacy of glatiramer
acetate in neuromyelitis optica spectrum disorder: a multicenter
retrospective study. J Neurol. 2016;263:575–82.
22. Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, Hellwig K,
Pache F, Ruprecht K, Havla J, et al. Neuromyelitis optica: Evaluation of 871
attacks and 1153 treatment courses. Ann Neurol. 2016;79:206–16.
23. Trebst C, Berthele A, Jarius S, Kumpfel T, Schippling S, Wildemann B, Wilke C.
[Diagnosis and treatment of neuromyelitis optica. Consensus recommendations
of the Neuromyelitis Optica Study Group]. Nervenarzt. 2011;82:768–77.
24. Jarius S, Probst C, Borowski K, Franciotta D, Wildemann B, Stoecker W,
Wandinger KP. Standardized method for the detection of antibodies to
aquaporin-4 based on a highly sensitive immunofluorescence assay
employing recombinant target antigen. J Neurol Sci. 2010;291:52–6.
Jarius et al. Journal of Neuroinflammation  (2016) 13:281 Page 22 of 23
25. Jarius S, Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological
marker of neuromyelitis optica: a critical review of the literature. Brain
Pathol. 2013;23:661–83.
26. Jarius S, Paul F, Fechner K, Ruprecht K, Kleiter I, Franciotta D, Ringelstein M,
Pache F, Aktas O, Wildemann B. Aquaporin-4 antibody testing: direct
comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus
M23-AQP4-DNA-transfected cells as antigenic substrate. J
Neuroinflammation. 2014;11:129.
27. Kremer L, Mealy M, Jacob A, Nakashima I, Cabre P, Bigi S, Paul F, Jarius S,
Aktas O, Elsone L, et al. Brainstem manifestations in neuromyelitis optica:
a multicenter study of 258 patients. Mult Scler. 2014;20:843-7.
28. Asgari N, Skejoe HP, Lillevang ST, Steenstrup T, Stenager E, Kyvik KO.
Modifications of longitudinally extensive transverse myelitis and brainstem
lesions in the course of neuromyelitis optica (NMO): a population-based,
descriptive study. BMC Neurol. 2013;13:33.
29. Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, Kleiter I,
Chitnis T. Demographic and clinical features of neuromyelitis optica: A
review. Mult Scler. 2015;21:845–53.
30. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical
course of neuromyelitis optica (Devic’s syndrome). Neurology. 1999;53:1107–14.
31. Apiwattanakul M, Popescu BF, Matiello M, Weinshenker BG, Lucchinetti CF,
Lennon VA, McKeon A, Carpenter AF, Miller GM, Pittock SJ. Intractable
vomiting as the initial presentation of neuromyelitis optica. Ann Neurol.
2010;68:757–61.
32. Asgari N, Skejoe HP, Lennon VA. Evolution of longitudinally extensive transverse
myelitis in an aquaporin-4 IgG-positive patient. Neurology. 2013;81:95–6.
33. Iorio R, Lucchinetti CF, Lennon VA, Farrugia G, Pasricha PJ, Weinshenker BG,
Pittock SJ. Intractable nausea and vomiting from autoantibodies against a
brain water channel. Clin Gastroenterol Hepatol. 2013;11:240–5.
34. Popescu BF, Lennon VA, Parisi JE, Howe CL, Weigand SD, Cabrera-Gomez
JA, Newell K, Mandler RN, Pittock SJ, Weinshenker BG, Lucchinetti CF.
Neuromyelitis optica unique area postrema lesions: Nausea, vomiting, and
pathogenic implications. Neurology. 2011;76:1229–37.
35. Riphagen J, Modderman P, Verrips A. Hiccups, nausea, and vomiting: water
channels under attack! Lancet. 2010;375:954.
36. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised
diagnostic criteria for neuromyelitis optica laboratory features, treatment
responses, and long-term outcome. Neurology. 2006;66:1485–9.
37. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC,
Castle D, Mandell JW, Lee KS, et al. Structural and functional features of
central nervous system lymphatic vessels. Nature. 2015;523:337–41.
38. Kim W, Kim SH, Lee SH, Li XF, Kim HJ. Brain abnormalities as an initial manifestation
of neuromyelitis optica spectrum disorder. Mult Scler. 2011;17:1107–12.
39. Kim JE, Kim SM, Ahn SW, Lim BC, Chae JH, Hong YH, Park KS, Sung JJ, Lee
KW. Brain abnormalities in neuromyelitis optica. J Neurol Sci. 2011;302:43–8.
40. Saji E, Arakawa M, Yanagawa K, Toyoshima Y, Yokoseki A, Okamoto K, Otsuki
M, Akazawa K, Kakita A, Takahashi H, et al. Cognitive impairment and
cortical degeneration in neuromyelitis optica. Ann Neurol. 2013;73:65–76.
41. Tahara M, Ito R, Tanaka K, Tanaka M. Cortical and leptomeningeal involvement
in three cases of neuromyelitis optica. Eur J Neurol. 2012;19:e47–8.
42. Jarius S, Wildemann B. ‘Noteomielite’ accompanied by acute amaurosis
(1844). An early case of neuromyelitis optica. J Neurol Sci. 2012;313:182–4.
43. Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, Klawiter EC,
Sato DK, de Seze J, Wuerfel J, et al. MRI characteristics of neuromyelitis optica
spectrum disorder: an international update. Neurology. 2015;84:1165–73.
44. Lepur D, Peterkovic V, Kalabric-Lepur N. Neuromyelitis optica with CSF
examination mimicking bacterial meningomyelitis. Neurol Sci. 2009;30:51–4.
45. Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, Bergamaschi R,
Rommer P, Kleiter I, Stich O, Reuss R, et al. Cerebrospinal fluid findings in
aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar
punctures. J Neurol Sci. 2011;306:82–90.
46. Jarius S, Wildemann B. Aquaporin-4 antibodies, CNS acidosis and neuromyelitis
optica: A potential link. Med Hypotheses. 2013;81:1090–5.
47. Jarius S, Franciotta D, Paul F, Ruprecht K, Bergamaschi R, Rommer PS, Reuss R,
Probst C, Kristoferitsch W, Wandinger KP, Wildemann B. Cerebrospinal fluid
antibodies to aquaporin-4 in neuromyelitis optica and related disorders:
frequency, origin, and diagnostic relevance. J Neuroinflammation. 2010;7:52.
48. Kothur K, Wienholt L, Tantsis EM, Earl J, Bandodkar S, Prelog K, Tea F,
Ramanathan S, Brilot F, Dale RC. B Cell, Th17, and Neutrophil Related
Cerebrospinal Fluid Cytokine/Chemokines Are Elevated in MOG Antibody
Associated Demyelination. PLoS One. 2016;11:e0149411.
49. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of
neuromyelitis optica in the United States: a multicenter analysis. Arch
Neurol. 2012;69:1176–80.
50. Heerlein K, Jarius S, Jacobi C, Rohde S, Storch-Hagenlocher B, Wildemann B.
Aquaporin-4 antibody positive longitudinally extensive transverse myelitis
following varicella zoster infection. J Neurol Sci. 2009;276:184–6.
51. Jarius S, Paul F, Martins da Silva A, Leite MI, Waters P, Littleton E, Franciotta
D, Palace J, Zipp F, Vincent A. Neuromyelitis optica and longitudinally
extensive transverse myelitis following thymectomy for myasthenia gravis.
Mult Scler. 2007;13:P534.
52. Leite MI, Coutinho E, Lana-Peixoto M, Apostolos S, Waters P, Sato D,
Melamud L, Marta M, Graham A, Spillane J, et al. Myasthenia gravis and
neuromyelitis optica spectrum disorder: a multicenter study of 16 patients.
Neurology. 2012;78:1601–7.
53. Nishiyama S, Ito T, Misu T, Takahashi T, Kikuchi A, Suzuki N, Jin K, Aoki M,
Fujihara K, Itoyama Y. A case of NMO seropositive for aquaporin-4 antibody
more than 10 years before onset. Neurology. 2009;72:1960–1.
54. Wingerchuk DM, Lucchinetti CF. Comparative immunopathogenesis of
acute disseminated encephalomyelitis, neuromyelitis optica, and multiple
sclerosis. Curr Opin Neurol. 2007;20:343–50.
55. Wildemann B, Jarius S, Hartmann M, Regula JU, Hametner C. Acute
disseminated encephalomyelitis following vaccination against human
papilloma virus. Neurology. 2009;72:2132–3.
56. Furukawa Y, Komai K, Yamada M. Neuromyelitis optica after Japanese
encephalitis vaccination. Eur J Neurol. 2011;18:e26–7.
57. Menge T, Cree B, Saleh A, Waterboer T, Berthele A, Kalluri SR, Hemmer B,
Aktas O, Hartung HP, Methner A, Kieseier BC. Neuromyelitis optica following
human papillomavirus vaccination. Neurology. 2012;79:285–7.
58. Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE, Voloschin A, Baehring JM,
Shimazaki H, Koide R, King D, et al. Paraneoplastic anti-N-methyl-D-aspartate
receptor encephalitis associated with ovarian teratoma. Ann Neurol.
2007;61:25–36.
59. Phi JH, Park SH, Paek SH, Kim SK, Lee YJ, Park CK, Cho BK, Lee DH, Wang KC.
Expression of Sox2 in mature and immature teratomas of central nervous
system. Mod Pathol. 2007;20:742–8.
60. Bartakova A, Ondic O, Presl J, Vlasak P, Bouda J. Oligodendroglioma
originating in mature cystic teratoma. J Obstet Gynaecol. 2015;1–2.
61. Unal B, Gulec F, Sedele M. Oligodendroglioma arising in mature cystic
teratoma. Case Rep Oncol Med. 2014;2014:745462.
62. Opris I, Ducrotoy V, Bossut J, Lamy A, Sabourin JC. Oligodendroglioma arising
in an ovarian mature cystic teratoma. Int J Gynecol Pathol. 2009;28:367–71.
63. Zannoni GF, Fadda G, Scambia G, Capelli A, Carbone A. Oligodendroglioma
arising within a mature cystic ovarian teratoma: case report and review of
the literature. Acta Obstet Gynecol Scand. 2002;81:896–7.
64. Nakashima I, Takahashi T, Cree BA, Kim HJ, Suzuki C, Genain CP, Vincent
T, Fujihara K, Itoyama Y, Bar-Or A. Transient increases in anti-aquaporin-4
antibody titers following rituximab treatment in neuromyelitis optica, in
association with elevated serum BAFF levels. J Clin Neurosci.
2011;18:997–8.
65. Palace J, Leite MI, Nairne A, Vincent A. Interferon Beta treatment in
neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers.
Arch Neurol. 2010;67:1016–7.
66. Shimizu Y, Yokoyama K, Misu T, Takahashi T, Fujihara K, Kikuchi S, Itoyama Y,
Iwata M. Development of extensive brain lesions following interferon beta
therapy in relapsing neuromyelitis optica and longitudinally extensive
myelitis. J Neurol. 2008;255:305–7.
67. Warabi Y, Matsumoto Y, Hayashi H. Interferon beta-1b exacerbates multiple
sclerosis with severe optic nerve and spinal cord demyelination. J Neurol
Sci. 2007;252:57–61.
68. Khorooshi R, Wlodarczyk A, Asgari N, Owens T. Neuromyelitis optica-like
pathology is dependent on type I interferon response. Exp Neurol.
2013;247:744–7.
69. Asgari N, Kyvik KO, Steenstrup T, Stenager E, Lillevang ST. Antibodies against
interferon-beta in neuromyelitis optica patients. J Neurol Sci. 2014;339:52–6.
Jarius et al. Journal of Neuroinflammation  (2016) 13:281 Page 23 of 23
